Skip to content
← All treatment topics

TREATMENT READING

Colon Cancer

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

76 sections
  1. Treatment Option Overview for Colon Cancer
  2. Primary Surgical Therapy
  3. Adjuvant Chemotherapy
  4. Chemotherapy regimens
  5. Capecitabine and fluorouracil dosing
  6. Adjuvant Radiation Therapy
  7. Treatment of Stage 0 Colon Cancer
  8. Treatment Options for Stage 0 Colon Cancer
  9. Surgery
  10. Treatment of Stage I Colon Cancer
  11. Treatment Options for Stage I Colon Cancer
  12. Surgery
  13. Treatment of Stage II Colon Cancer
  14. Treatment Options for Stage II Colon Cancer
  15. Surgery
  16. Adjuvant chemotherapy
  17. Treatment of Stage III Colon Cancer
  18. Treatment Options for Stage III Colon Cancer
  19. Surgery
  20. Adjuvant chemotherapy
  21. Chemotherapy regimens before 2000
  22. Chemotherapy regimens after 2000
  23. Capecitabine and oxaliplatin
  24. Oxaliplatin length of therapy
  25. Treatment of Stage IV and Recurrent Colon Cancer
  26. Treatment Options for Liver Metastasis
  27. Surgery
  28. Neoadjuvant chemotherapy for unresectable liver metastases
  29. Local ablation
  30. Adjuvant or neoadjuvant chemotherapy for resectable liver metastases
  31. Intra-arterial chemotherapy after liver resection
  32. Treatment Options for Stage IV and Recurrent Colon Cancer
  33. Surgery
  34. Systemic therapy
  35. 5-FU
  36. Capecitabine
  37. Irinotecan
  38. Oxaliplatin
  39. Bevacizumab
  40. FOLFOXIRI
  41. Cetuximab
  42. Ziv-aflibercept
  43. Ramucirumab
  44. Panitumumab
  45. Anti-EGFR antibody versus anti-VEGF antibody with first-line chemotherapy
  46. Trifluridine-tipiracil
  47. Regorafenib
  48. Fruquintinib
  49. Encorafenib with cetuximab in patients with BRAF V600E variants
  50. Sotorasib with panitumumab for patients with KRAS G12C variants
  51. Immunotherapy
  52. First-line immunotherapy
  53. Pembrolizumab monotherapy
  54. Nivolumab and ipilimumab
  55. Second-line immunotherapy
  56. Pembrolizumab monotherapy
  57. Nivolumab monotherapy
  58. Nivolumab and ipilimumab
  59. Certain factors affect prognosis (chance of recovery) and treatment options.
  60. Colon cancer can recur (come back) after it has been treated.
  61. Treatment Option Overview
  62. Key Points
  63. There are different types of treatment for people with colon cancer.
  64. The following types of treatment are used:
  65. Surgery
  66. Chemotherapy
  67. Radiation therapy
  68. Targeted therapy
  69. Immunotherapy
  70. New types of treatment are being tested in clinical trials.
  71. Treatment for colon cancer may cause side effects.
  72. Follow-up care may be needed.
  73. Treatment of Stage 0 (carcinoma in situ)
  74. Treatment of Stages I and II Colon Cancer
  75. Treatment of Stage III Colon Cancer
  76. Treatment of Stage IV and Recurrent Colon Cancer

Health professional

Treatment Option Overview for Colon Cancer

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Table 6. Treatment Options for Colon Cancer
Stage (TNM Staging Criteria)Treatment Options
Stage 0 Colon CancerSurgery
Stage I Colon CancerSurgery
Stage II Colon CancerSurgery
Adjuvant chemotherapy (under clinical evaluation)
Stage III Colon CancerSurgery
Clinical trials
Liver MetastasisSurgery
Neoadjuvant chemotherapy
Local ablation
Adjuvant chemotherapy
Intra-arterial chemotherapy
Clinical trials
Stage IV and Recurrent Colon CancerSurgery
Systemic therapy
Immunotherapy
Clinical trials

Sources: Stage (TNM Staging Criteria) · Surgery · Surgery · Surgery · Adjuvant chemotherapy · Surgery · Clinical trials · Surgery · Neoadjuvant chemotherapy · Local ablation · Adjuvant chemotherapy · Intra-arterial chemotherapy · Clinical trials · Surgery · Systemic therapy · Immunotherapy · Clinical trials

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional · Treatment Option Overview for Colon Cancer

Primary Surgical Therapy

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Standard treatment for patients with colon cancer has been open surgical resection of the primary and regional lymph nodes for localized disease.

The role of laparoscopic techniques [1-4] in the treatment of colon cancer has been examined in two studies.

Sources: 1 · 4

Evidence (laparoscopic techniques):

A multicenter, prospective, randomized, noninferiority trial (NCCTG-934653 [NCT00002575]) compared laparoscopic-assisted colectomy (LAC) with open colectomy in 872 patients.

Sources: NCCTG-934653

A multicenter, prospective, randomized, noninferiority trial (NCCTG-934653 [NCT00002575]) compared laparoscopic-assisted colectomy (LAC) with open colectomy in 872 patients.

At a median follow-up of 4.4 years, 3-year recurrence rates (16% LAC vs. 18% open colectomy; hazard ratio [HR] for recurrence, 0.86; 95% confidence interval [CI], 0.63–1.17; P = .32) and 3-year overall survival (OS) rates (86% LAC vs. 85% open colectomy; HRdeath in LAC, 0.91; 95% CI, 0.68–1.21; P = .51) were similar in both groups for all stages of disease evaluated. Tumor recurrence in surgical incisions was less than 1% for both groups.[5][Level of evidence A1]

Sources: 5 · Level of evidence A1

Decreased hospital stay (5 days LAC vs. 6 days open colectomy, P < .001) and decreased use of analgesics were reported in the LAC group. A 21% conversion rate from LAC to open procedure was shown.

This study excluded patients with locally advanced disease, transverse colon and rectal tumor locations, and perforated lesions. Each of the 66 surgeons participating in the trial had performed at least 20 LACs and were accredited for study participation after independent videotape review assured appropriate oncologic and surgical principles were maintained.[5] The quality-of-life component of this trial was published separately and minimal short-term quality-of-life benefits with LAC were reported.[6][Level of evidence A3]

Sources: 5 · 6 · Level of evidence A3

One small, single-institution randomized study of 219 patients showed that the LAC procedure was independently associated with reduced tumor recurrence on multivariate analysis.[7][Level of evidence A1]

Sources: 7 · Level of evidence A1

Surgery is curative in 25% to 40% of highly selected patients who develop resectable metastases in the liver and lung. Improved surgical techniques and advances in preoperative imaging have allowed for better patient selection for resection.

Health professional · Treatment Option Overview for Colon Cancer

Adjuvant Chemotherapy

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

The potential value of adjuvant chemotherapy for patients with stage II colon cancer is controversial. Pooled analyses and meta-analyses have suggested a 2% to 4% improvement in OS for patients treated with adjuvant fluorouracil (5-FU)–based therapy compared with observation.[8-10] For more information, see the Treatment of Stage II Colon Cancer section.

Sources: 8 · 10 · Treatment of Stage II Colon Cancer

Before 2000, 5-FU was the only useful cytotoxic chemotherapy in the adjuvant setting for patients with stage III colon cancer. Since 2000, capecitabine has been established as an equivalent alternative to 5-FU and leucovorin (5-FU/LV). The addition of oxaliplatin to 5-FU/LV has been shown to improve OS compared with 5-FU/LV alone. For more information, see the Treatment of Stage III Colon Cancer section.

Sources: Treatment of Stage III Colon Cancer

Health professional · Treatment Option Overview for Colon Cancer / Adjuvant Chemotherapy

Chemotherapy regimens

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Table 7 describes the chemotherapy regimens used to treat colon cancer.

Sources: Table 7

Table 7. Drug Combinations Used to Treat Colon Cancer
Regimen NameDrug CombinationDose
5-FU = fluorouracil; AIO = Arbeitsgemeinschaft Internistische Onkologie; bid = twice a day; IV = intravenous; LV = leucovorin.
AIO or German AIOFolic acid, 5-FU, and irinotecanIrinotecan (100 mg/m2) and LV (500 mg/m2) administered as 2-hour infusions on d 1, followed by 5-FU (2,000 mg/m2) IV bolus administered via ambulatory pump weekly over 24 h, 4 times a y (52 wk).
CAPOXCapecitabine and oxaliplatinCapecitabine (1,000 mg/m2) bid on d 1–14, plus oxaliplatin (70 mg/m2) on d 1 and 8 every 3 wk.
DouillardFolic acid, 5-FU, and irinotecanIrinotecan (180 mg/m2) administered as a 2-h infusion on d 1, LV (200 mg/m2) administered as a 2-h infusion on d 1 and 2, followed by a loading dose of 5-FU (400 mg/m2) IV bolus, then 5-FU (600 mg/m2) administered via ambulatory pump over 22 h every 2 wk on d 1 and 2.
FOLFIRILV, 5-FU, and irinotecanIrinotecan (180 mg/m2) and LV (400 mg/m2) administered as 2-h infusions on d 1, followed by a loading dose of 5-FU (400 mg/m2) IV bolus administered on d 1, then 5-FU (2,400–3,000 mg/m2) administered via ambulatory pump over 46 h every 2 wk.
FOLFOX-4Oxaliplatin, LV, and 5-FUOxaliplatin (85 mg/m2) administered as a 2-h infusion on d 1, LV (200 mg/m2) administered as a 2-h infusion on d 1 and 2, followed by a loading dose of 5-FU (400 mg/m2) IV bolus, then 5-FU (600 mg/m2) administered via ambulatory pump over 22 h every 2 wk on d 1 and 2.
FOLFOX-6Oxaliplatin, LV, and 5-FUOxaliplatin (85–100 mg/m2) and LV (400 mg/m2) administered as 2-h infusions on d 1, followed by a loading dose of 5-FU (400 mg/m2) IV bolus on d 1, then 5-FU (2,400–3,000 mg/m2) administered via ambulatory pump over 46 h every 2 wk.
FOLFOXIRIIrinotecan, oxaliplatin, LV, 5-FUIrinotecan (165 mg/m2) administered as a 60-min infusion, then concomitant infusion of oxaliplatin (85 mg/m2) and LV (200 mg/m2) over 120 min, followed by 5-FU (3,200 mg/m2) administered as a 48-h continuous infusion.
FUFOX5-FU, LV, and oxaliplatinOxaliplatin (50 mg/m2) plus LV (500 mg/m2) plus 5-FU (2,000 mg/m2) administered as a 22-h continuous infusion on d 1, 8, 22, and 29 every 36 d.
FUOX5-FU plus oxaliplatin5-FU (2,250 mg/m2) administered as a continuous infusion over 48 h on d 1, 8, 15, 22, 29, and 36 plus oxaliplatin (85 mg/m2) on d 1, 15, and 29 every 6 wk.
IFL (or Saltz)Irinotecan, 5-FU, and LVIrinotecan (125 mg/m2) plus 5-FU (500 mg/m2) IV bolus and LV (20 mg/m2) IV bolus administered weekly for 4 out of 6 wk.
XELOXCapecitabine plus oxaliplatinOral capecitabine (1,000 mg/m2) administered bid for 14 d plus oxaliplatin (130 mg/m2) on d 1 every 3 wk.

Health professional · Treatment Option Overview for Colon Cancer / Adjuvant Chemotherapy

Capecitabine and fluorouracil dosing

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

The DPYD gene encodes an enzyme that catabolizes pyrimidines and fluoropyrimidines, like capecitabine and fluorouracil. An estimated 1% to 2% of the population has germline pathogenic variants in DPYD, which lead to reduced DPD protein function and an accumulation of pyrimidines and fluoropyrimidines in the body.[11,12] Patients with the DPYD*2A variant who receive fluoropyrimidines may experience severe, life-threatening toxicities that are sometimes fatal. Many other DPYD variants have been identified, with a range of clinical effects.[11-13] Fluoropyrimidine avoidance or a dose reduction of 50% may be recommended based on the patient's DPYD genotype and number of functioning DPYD alleles.[14-16] DPYD genetic testing costs less than $200, but insurance coverage varies due to a lack of national guidelines.[17] In addition, testing may delay therapy by 2 weeks, which would not be advisable in urgent situations. This controversial issue requires further evaluation.[18]

Sources: 11 · 12 · 11 · 13 · 14 · 16 · 17 · 18

Health professional · Treatment Option Overview for Colon Cancer

Adjuvant Radiation Therapy

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

While combined modality therapy with chemotherapy and radiation therapy has a significant role in the management of patients with rectal cancer (below the peritoneal reflection), the role of adjuvant radiation therapy for patients with colon cancer (above the peritoneal reflection) is not well defined. Patterns-of-care analyses and single-institution retrospective reviews suggest a role for radiation therapy in certain high-risk subsets of colon cancer patients (e.g., T4, tumor location in immobile sites, local perforation, obstruction, and residual disease postresection).[19-24]

Sources: 19 · 24

Evidence (adjuvant radiation therapy):

A phase III, randomized, intergroup study evaluated the benefit of adding radiation therapy to surgery and chemotherapy with 5-FU-levamisole in selected patients with high-risk colon cancer (e.g., T4; or T3, N1–N2 ascending and/or descending colon).[25]

Sources: 25

A phase III, randomized, intergroup study evaluated the benefit of adding radiation therapy to surgery and chemotherapy with 5-FU-levamisole in selected patients with high-risk colon cancer (e.g., T4; or T3, N1–N2 ascending and/or descending colon).[25]

This clinical trial closed early secondary to inadequate patient accrual. An analysis of 222 enrolled patients (the original goal was 700 patients) demonstrated no relapse or OS benefit for the group that received radiation therapy, although the sample size and statistical power were inadequate to exclude benefit.

Adjuvant radiation therapy has no current standard role in the management of patients with colon cancer following curative resection, although it may have a role for patients with residual disease.

Health professional

Treatment of Stage 0 Colon Cancer

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Stage 0 colon cancer is the most superficial of all the lesions and is limited to the mucosa without invasion of the lamina propria. Because of its superficial nature, the surgical procedure may be limited.

Health professional · Treatment of Stage 0 Colon Cancer

Treatment Options for Stage 0 Colon Cancer

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Treatment options for stage 0 colon cancer include:

Sources: stage 0 colon cancer

Surgery.

Sources: Surgery

Health professional · Treatment of Stage 0 Colon Cancer / Treatment Options for Stage 0 Colon Cancer

Surgery

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Surgical options include local excision or simple polypectomy with clear margins, or colon resection for larger lesions not amenable to local excision.

Health professional

Treatment of Stage I Colon Cancer

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Because of its localized nature, stage I colon cancer has a high cure rate.

Health professional · Treatment of Stage I Colon Cancer

Treatment Options for Stage I Colon Cancer

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Treatment options for stage I colon cancer include:

Sources: stage I colon cancer

Surgery. Wide surgical resection and anastomosis.

Sources: Surgery

Health professional · Treatment of Stage I Colon Cancer / Treatment Options for Stage I Colon Cancer

Surgery

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Evidence (laparoscopic techniques):

The role of laparoscopic techniques [1-4] in the treatment of colon cancer was examined in a multicenter, prospective, randomized trial (NCCTG-934653 [NCT00002575]) comparing laparoscopic-assisted colectomy (LAC) with open colectomy.

Sources: 1 · 4 · NCCTG-934653

The role of laparoscopic techniques [1-4] in the treatment of colon cancer was examined in a multicenter, prospective, randomized trial (NCCTG-934653 [NCT00002575]) comparing laparoscopic-assisted colectomy (LAC) with open colectomy.

Three-year recurrence rates and 3-year overall survival rates were similar in the two groups. For more information, see the Primary Surgical Therapy section.

Sources: Primary Surgical Therapy

The quality-of-life component of this trial has been published and minimal short-term quality-of-life benefits with LAC were reported.[5][Level of evidence A3]

Sources: 5 · Level of evidence A3

Health professional

Treatment of Stage II Colon Cancer

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage II Colon Cancer

Treatment Options for Stage II Colon Cancer

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Treatment options for stage II colon cancer include:

Sources: stage II colon cancer

Surgery. Wide surgical resection and anastomosis.

Sources: Surgery

Adjuvant chemotherapy (under clinical evaluation).

Sources: Adjuvant chemotherapy

Health professional · Treatment of Stage II Colon Cancer / Treatment Options for Stage II Colon Cancer

Surgery

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Evidence (laparoscopic techniques):

The role of laparoscopic techniques [1-4] in the treatment of colon cancer was examined in a multicenter, prospective, randomized trial (NCCTG-934653 [NCT00002575]) comparing laparoscopic-assisted colectomy (LAC) to open colectomy.

Sources: 1 · 4 · NCCTG-934653

The role of laparoscopic techniques [1-4] in the treatment of colon cancer was examined in a multicenter, prospective, randomized trial (NCCTG-934653 [NCT00002575]) comparing laparoscopic-assisted colectomy (LAC) to open colectomy.

Three-year recurrence rates and 3-year overall survival (OS) rates were similar in the two groups. For more information, see the Primary Surgical Therapy section.

Sources: Primary Surgical Therapy

The quality-of-life component of this trial reported minimal short-term quality-of-life benefits with LAC.[4][Level of evidence A3]

Sources: 4 · Level of evidence A3

Health professional · Treatment of Stage II Colon Cancer / Treatment Options for Stage II Colon Cancer

Adjuvant chemotherapy

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

The potential value of adjuvant chemotherapy for patients with stage II colon cancer remains controversial. Although subgroups of patients with stage II colon cancer may be at higher-than-average risk for recurrence (including those with anatomical features such as tumor adherence to adjacent structures, perforation, and complete obstruction),[5-7] evidence is inconsistent that adjuvant fluorouracil (5-FU)–based chemotherapy is associated with an improved OS compared with surgery alone.[8]

Sources: 5 · 7 · 8

Features in patients with stage II colon cancer that are associated with an increased risk of recurrence include:

Inadequate lymph node sampling.

T4 disease.

Involvement of the visceral peritoneum.

A poorly differentiated histology.

The decision to use adjuvant chemotherapy for patients with stage II colon cancer is complicated and requires thoughtful consideration by both patients and their physicians. Adjuvant therapy is not indicated for most patients unless they are entered into a clinical trial.

Evidence (adjuvant chemotherapy):

The GRECCR-03 (NCT00046995) and NCRI-QUASAR1 (NCT00005586) trials evaluated the use of systemic or regional chemotherapy or biological therapy. Following surgery, patients can be considered for entry into a carefully controlled clinical trial.

Sources: GRECCR-03 · NCRI-QUASAR1

Investigators from the National Surgical Adjuvant Breast and Bowel Project have indicated that the reduction in risk of recurrence by adjuvant therapy in patients with stage II disease is of similar magnitude to the benefit seen in patients with stage III disease treated with adjuvant therapy, though an OS advantage has not been established.[9]

Sources: 9

A meta-analysis of 1,000 stage II patients whose experience was amalgamated from a series of trials indicates a 2% advantage in disease-free survival at 5 years when adjuvant therapy–treated patients treated with 5-FU/leucovorin are compared with untreated controls.[10][Level of evidence B1]; [11]

Sources: 10 · Level of evidence B1 · 11

The Cancer Care Ontario Practice Guideline Initiative Gastrointestinal Cancer Disease Site Group undertook a meta-analysis of the English language–published literature consisting of randomized trials in which adjuvant chemotherapy was compared with observation for patients with stage II colon cancer.

The Cancer Care Ontario Practice Guideline Initiative Gastrointestinal Cancer Disease Site Group undertook a meta-analysis of the English language–published literature consisting of randomized trials in which adjuvant chemotherapy was compared with observation for patients with stage II colon cancer.

The mortality risk ratio was 0.87 (95% confidence interval, 0.75–1.01; P = .07).[12]

Sources: 12

Based on these data, the American Society of Clinical Oncology issued a guideline stating “direct evidence from randomized controlled trials does not support the routine use of adjuvant chemotherapy for patients with stage II colon cancer.”[13]

Sources: 13

Health professional

Treatment of Stage III Colon Cancer

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Stage III colon cancer denotes lymph node involvement. Studies have indicated that the number of lymph nodes involved affects prognosis; patients with one to three involved nodes have a significantly better survival than those with four or more involved nodes.

Health professional · Treatment of Stage III Colon Cancer

Treatment Options for Stage III Colon Cancer

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Treatment options for stage III colon cancer include:

Sources: stage III colon cancer

Surgery.

Sources: Surgery

Adjuvant chemotherapy.

Sources: Adjuvant chemotherapy

Clinical trials. Eligible patients can consider enrollment in carefully controlled clinical trials comparing various postoperative chemotherapy regimens.[1]

Sources: 1

Health professional · Treatment of Stage III Colon Cancer / Treatment Options for Stage III Colon Cancer

Surgery

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Surgery for stage III colon cancer is wide surgical resection and anastomosis.

Evidence (laparoscopic techniques):

The role of laparoscopic techniques [2-5] in the treatment of colon cancer was examined in a multicenter, prospective, randomized trial (NCCTG-934653 [NCT00002575]) comparing laparoscopic-assisted colectomy (LAC) with open colectomy.

Sources: 2 · 5 · NCCTG-934653

The role of laparoscopic techniques [2-5] in the treatment of colon cancer was examined in a multicenter, prospective, randomized trial (NCCTG-934653 [NCT00002575]) comparing laparoscopic-assisted colectomy (LAC) with open colectomy.

Three-year recurrence rates and 3-year overall survival (OS) rates were similar in the two groups. For more information, see the Primary Surgical Therapy section.

Sources: Primary Surgical Therapy

The quality-of-life component of this trial has been published and minimal short-term quality-of-life benefits with LAC were reported.[6][Level of evidence A3]

Sources: 6 · Level of evidence A3

Health professional · Treatment of Stage III Colon Cancer / Treatment Options for Stage III Colon Cancer

Adjuvant chemotherapy

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage III Colon Cancer / Treatment Options for Stage III Colon Cancer / Adjuvant chemotherapy

Chemotherapy regimens before 2000

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Before 2000, fluorouracil (5-FU) was the only useful cytotoxic chemotherapy in the adjuvant setting for patients with stage III colon cancer. Many of the early randomized studies of 5-FU in the adjuvant setting failed to show a significant improvement in survival for patients.[7-10] These trials employed 5-FU alone or 5-FU/semustine.

Sources: 7 · 10

Evidence (5-FU alone and 5-FU/semustine):

The North Central Cancer Treatment Group conducted a randomized trial comparing surgical resection alone with postoperative levamisole or levamisole/5-FU.[11][Level of evidence A1]

Sources: 11 · Level of evidence A1

The North Central Cancer Treatment Group conducted a randomized trial comparing surgical resection alone with postoperative levamisole or levamisole/5-FU.[11][Level of evidence A1]

A significant improvement in disease-free survival (DFS) was observed for patients with stage III colon cancer who received levamisole/5-FU, but OS benefits were of borderline statistical significance.

An absolute survival benefit of approximately 12% (49% vs. 37%) was seen in patients with stage III disease treated with levamisole/5-FU.

In a large confirmatory intergroup trial, levamisole/5-FU- prolonged DFS and OS in patients with stage III colon cancer compared with patients who received no treatment after surgery.[12][Level of evidence A1] Levamisole alone did not confer these benefits.

Sources: 12 · Level of evidence A1

Subsequent studies tested the combination of 5-FU/leucovorin (5-FU/LV) in the adjuvant treatment of patients with resected carcinoma of the colon.

Subsequent studies tested the combination of 5-FU/leucovorin (5-FU/LV) in the adjuvant treatment of patients with resected carcinoma of the colon.

Results of multiple randomized trials that have enrolled more than 4,000 patients comparing adjuvant chemotherapy with 5-FU/LV to surgery or 5-FU/semustine/vincristine demonstrate a relative reduction in mortality of between 22% and 33% (3-year OS of 71%–78% increased to 75%–84%).[13-15]

Sources: 13 · 15

The completed Intergroup trial 0089 (INT-0089 [NCT00201331]) randomly assigned 3,794 patients with high-risk stage II or stage III colon cancer to one of the following four treatment arms:[16]Results:

Sources: INT-0089 · 16

The completed Intergroup trial 0089 (INT-0089 [NCT00201331]) randomly assigned 3,794 patients with high-risk stage II or stage III colon cancer to one of the following four treatment arms:[16]Results:

The Mayo Clinic regimen administered for a total of six cycles.

The Roswell Park regimen administered for a total of four cycles.

The Mayo Clinic regimen administered with levamisole for six cycles.

The levamisole regimen administered for a total of 1 year.

Five-year OS ranged from 49% for the Mayo Clinic regimen with levamisole to 60% for the Mayo Clinic regimen, and there were no statistically significant differences among treatment arms.[16][Level of evidence A1]

Sources: 16 · Level of evidence A1

A preliminary report in November 1997 demonstrated a statistically significant advantage for OS for the Mayo Clinic regimen with levamisole compared with the levamisole regimen. This difference became insignificant with longer follow-up.

Overall, grade 3 or greater toxicity occurred more frequently for the Mayo Clinic regimen and the Mayo Clinic regimen with levamisole. In addition, the Mayo Clinic regimen was significantly more toxic with levamisole than without levamisole.

The death rate for all four regimens ranged from 0.5% to 1%.

Because of its ease of use and its good toxicity profile, the Roswell Park regimen became the preferred adjuvant regimen used in the United States and was often the control arm in subsequent randomized studies.

In addition to INT-0089, multiple studies have refined the use of 5-FU/LV in the adjuvant setting and can be summarized as follows:

In addition to INT-0089, multiple studies have refined the use of 5-FU/LV in the adjuvant setting and can be summarized as follows:

Levamisole is unnecessary when using leucovorin.[16]

Sources: 16

Treatment that includes 6 to 8 months of 5-FU/LV is equivalent to 12 months of therapy.[17-19]

Sources: 17 · 19

Treatment that includes 24 weeks of adjuvant 5-FU/LV is equivalent to 36 weeks of therapy.[20]

Sources: 20

High-dose leucovorin is equivalent to low-dose leucovorin.[21]

Sources: 21

A meta-analysis of seven trials revealed no significant difference in efficacy or toxicity among patients aged 70 years or younger compared with patients older than 70 years.[22]

Sources: 22

An infusional de Gramont bolus and infusional 5-FU/LV schedule is safer than a bolus modified Mayo Clinic schedule of 5-FU/LV.[20]

Sources: 20

Health professional · Treatment of Stage III Colon Cancer / Treatment Options for Stage III Colon Cancer / Adjuvant chemotherapy

Chemotherapy regimens after 2000

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Capecitabine

Capecitabine is an oral fluoropyrimidine that undergoes a three-step enzymatic conversion to 5-FU with the last step occurring in the tumor cell. For patients with metastatic colon cancer, two studies have demonstrated the equivalence of capecitabine to 5-FU/LV.[23,24]

Sources: 23 · 24

For patients with stage III colon cancer, capecitabine provides equivalent outcome to intravenous 5-FU/LV.

Evidence (capecitabine):

A multicenter European study compared capecitabine (1,250 mg/m2) administered twice daily for days 1 to 14, then given every 21 days for eight cycles against the Mayo Clinic schedule of 5-FU and low-dose LV for patients with stage III colon cancer.[25]

Sources: 25

A multicenter European study compared capecitabine (1,250 mg/m2) administered twice daily for days 1 to 14, then given every 21 days for eight cycles against the Mayo Clinic schedule of 5-FU and low-dose LV for patients with stage III colon cancer.[25]

The study demonstrated that DFS at 3 years is equivalent for patients who received capecitabine or 5-FU/LV (hazard ratio [HR], 0.87; P < .001).[25][Level of evidence B1]

Sources: 25 · Level of evidence B1

Hand-foot syndrome and hyperbilirubinemia were significantly more common for patients receiving capecitabine, but diarrhea, nausea or vomiting, stomatitis, alopecia, and neutropenia were significantly less common.

Of patients receiving capecitabine, 57% required a dose modification.

For patients with stage III colon cancer in whom treatment with 5-FU/LV is planned, capecitabine is an equivalent alternative.

Oxaliplatin

Oxaliplatin has significant activity when combined with 5-FU/LV in patients with metastatic colorectal cancer.

Evidence (oxaliplatin):

In the 2,246 patients with resected stage II or stage III colon cancer in the completed Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer study (MOSAIC [NCT00275210]), the toxic effects and efficacy of FOLFOX-4 (oxaliplatin/LV/5-FU) were compared with the same 5-FU/LV regimen without oxaliplatin administered for 6 months.[26] Based on results from the MOSAIC trial, adjuvant FOLFOX-4 demonstrated prolonged OS for patients with stage III colon cancer compared with patients receiving 5-FU/LV without oxaliplatin.[27]

Sources: MOSAIC · 26 · 27

In the 2,246 patients with resected stage II or stage III colon cancer in the completed Multicenter International Study of Oxaliplatin/Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer study (MOSAIC [NCT00275210]), the toxic effects and efficacy of FOLFOX-4 (oxaliplatin/LV/5-FU) were compared with the same 5-FU/LV regimen without oxaliplatin administered for 6 months.[26] Based on results from the MOSAIC trial, adjuvant FOLFOX-4 demonstrated prolonged OS for patients with stage III colon cancer compared with patients receiving 5-FU/LV without oxaliplatin.[27]

The preliminary results of the study with 37 months of follow-up demonstrated a significant improvement in DFS at 3 years (77.8% vs. 72.9%; P = .01) in favor of FOLFOX-4. When initially reported, there was no difference in OS.[27][Level of evidence B1]

Sources: 27 · Level of evidence B1

Further follow-up at 6 years demonstrated that the OS for all patients (both stage II and stage III) who entered the study was not significantly different (OS, 78.5% vs. 76.0%; HR, 0.84; 95% confidence interval [CI], 0.71–1.00). On subset analysis, the 6-year OS in patients with stage III colon cancer was 72.9% in the patients receiving FOLFOX-4 and 68.7% in the patients receiving 5-FU/LV (HR, 0.80; 95% CI, 0.65–0.97; P = .023).[27][Level of evidence A1]

Sources: 27 · Level of evidence A1

Patients treated with FOLFOX-4 experienced more frequent toxic effects consisting mainly of neutropenia (41% >grade 3) and reversible peripheral sensorial neuropathy (12.4% >grade 3).

In a randomized phase III study (NSABP C-07 [NCT00004931]), 2,407 patients with stage II or stage III colon cancer were randomly assigned to adjuvant 5-FU/LV or fluorouracil-leucovorin-oxaliplatin (FLOX) (weekly 5-FU/LV with oxaliplatin administered on weeks 1, 3, and 5 of each 6-week cycle). DFS was the primary end point of the study.[28]

Sources: NSABP C-07 · 28

In a randomized phase III study (NSABP C-07 [NCT00004931]), 2,407 patients with stage II or stage III colon cancer were randomly assigned to adjuvant 5-FU/LV or fluorouracil-leucovorin-oxaliplatin (FLOX) (weekly 5-FU/LV with oxaliplatin administered on weeks 1, 3, and 5 of each 6-week cycle). DFS was the primary end point of the study.[28]

DFS was significantly longer in the treatment group who received FLOX, but OS was not significantly different. The DFS rate was 69.4% for patients who received FLOX and 64.2% for patients who received 5-FU/LV (HR, 0.82; 95% CI, 0.72–0.93; P = .0034).

The OS rate at 5 years was 80.2% for patients who received FLOX and 78.4% for patients who received 5-FU/LV (HR, 0.88; 95% CI, 0.75–1.02; P = .08).[28][Level of evidence B1]

Sources: 28 · Level of evidence B1

Grade 3 and grade 4 diarrhea was experienced by 36.9% of patients who received FLOX, and grade 3 and grade 4 dehydration was experienced by 16.1% of patients who received FLOX.

Most physicians have adopted FOLFOX as the standard of care because of toxicity concerns with weekly FLOX. FOLFOX has become the reference standard for the next generation of clinical trials for patients with stage III colon cancer.[27]

Sources: 27

Health professional · Treatment of Stage III Colon Cancer / Treatment Options for Stage III Colon Cancer / Adjuvant chemotherapy

Capecitabine and oxaliplatin

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

The combination of capecitabine and oxaliplatin (CAPOX) is an accepted standard therapy in patients with metastatic colorectal cancer.

Evidence (CAPOX):

CAPOX was evaluated in the adjuvant setting for patients with resected stage III colon cancer (capecitabine 1,000 mg/m2 bid on days 1 to 14 every 21 days and oxaliplatin 130 mg/m2 every 21 days for a total of 8 cycles).[29] A randomized phase III trial (NO16968 [NCT00069121]), randomly assigned 1,886 patients with stage III colon cancer to receive CAPOX or bolus 5FU-LV (Roswell Park or Mayo Clinic schedule).

Sources: 29 · NO16968

CAPOX was evaluated in the adjuvant setting for patients with resected stage III colon cancer (capecitabine 1,000 mg/m2 bid on days 1 to 14 every 21 days and oxaliplatin 130 mg/m2 every 21 days for a total of 8 cycles).[29] A randomized phase III trial (NO16968 [NCT00069121]), randomly assigned 1,886 patients with stage III colon cancer to receive CAPOX or bolus 5FU-LV (Roswell Park or Mayo Clinic schedule).

The 7-year DFS rates were 63% for patients who received CAPOX and 56% for patients who received bolus 5-FU/LV (HR, 0.8; 95% CI, 0.69–0.93; P = .004).

The 7-year OS rates were 73% for patients who received CAPOX and 67% for patients who received a bolus 5-FU/LV (HR, 0.83; 95% CI, 0.70–0.99; P = .04).[29][Level of evidence A1]

Sources: 29 · Level of evidence A1

Based on this trial, CAPOX has become an acceptable standard regimen for patients with stage III colon cancer.

Health professional · Treatment of Stage III Colon Cancer / Treatment Options for Stage III Colon Cancer / Adjuvant chemotherapy

Oxaliplatin length of therapy

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Given the high rate of disabling neuropathy, the duration of oxaliplatin adjuvant therapy became an open question.

Evidence (length of therapy for oxaliplatin):

The International Duration Evaluation of Adjuvant Therapy (IDEA) collaboration consisted of six separate randomized trials with regimens of 6 months versus 3 months of adjuvant oxaliplatin-based chemotherapy. The IDEA study was a prospective, preplanned pooled analysis of these concurrently conducted studies to evaluate the noninferiority of adjuvant therapy of either FOLFOX or CAPOX administered for 3 months versus 6 months. Noninferiority could be claimed if the upper limit of the two-sided 95% CI of the HR did not exceed 1.12.[30] From 2007 through 2015, 13,025 patients with stage III colon cancer were enrolled in six concurrent phase III trials. Of these patients, 12,834 patients met the criteria for intention-to-treat analysis. At a median follow-up of 41.8 months, noninferiority of 3 months versus 6 months was not confirmed in the modified intention-to-treat population (HR, 1.07; 95% CI, 1.00–1.15, P = .11 for noninferiority of 3 months).

Sources: 30

The International Duration Evaluation of Adjuvant Therapy (IDEA) collaboration consisted of six separate randomized trials with regimens of 6 months versus 3 months of adjuvant oxaliplatin-based chemotherapy. The IDEA study was a prospective, preplanned pooled analysis of these concurrently conducted studies to evaluate the noninferiority of adjuvant therapy of either FOLFOX or CAPOX administered for 3 months versus 6 months. Noninferiority could be claimed if the upper limit of the two-sided 95% CI of the HR did not exceed 1.12.[30] From 2007 through 2015, 13,025 patients with stage III colon cancer were enrolled in six concurrent phase III trials. Of these patients, 12,834 patients met the criteria for intention-to-treat analysis. At a median follow-up of 41.8 months, noninferiority of 3 months versus 6 months was not confirmed in the modified intention-to-treat population (HR, 1.07; 95% CI, 1.00–1.15, P = .11 for noninferiority of 3 months).

The 3-year DFS rates were 74.6% in the 3-month group and 75.5% in the 6-month group.

Neurotoxicity of grade 2 or higher was lower in the 3-month group (16.6% for patients who received FOLFOX and 14.2% for patients who received CAPOX) than in the 6-month group (47.7% for patients who received FOLFOX and 44.9% for patients who received CAPOX). Moreover, all other toxicities were substantially lower with 3 months of treatment than with 6 months.

A subgroup analyses observed:

The International Duration Evaluation of Adjuvant Therapy (IDEA) collaboration consisted of six separate randomized trials with regimens of 6 months versus 3 months of adjuvant oxaliplatin-based chemotherapy. The IDEA study was a prospective, preplanned pooled analysis of these concurrently conducted studies to evaluate the noninferiority of adjuvant therapy of either FOLFOX or CAPOX administered for 3 months versus 6 months. Noninferiority could be claimed if the upper limit of the two-sided 95% CI of the HR did not exceed 1.12.[30] From 2007 through 2015, 13,025 patients with stage III colon cancer were enrolled in six concurrent phase III trials. Of these patients, 12,834 patients met the criteria for intention-to-treat analysis. At a median follow-up of 41.8 months, noninferiority of 3 months versus 6 months was not confirmed in the modified intention-to-treat population (HR, 1.07; 95% CI, 1.00–1.15, P = .11 for noninferiority of 3 months). › A subgroup analyses observed:

Among patients receiving FOLFOX, 6 months of therapy was superior to 3 months of therapy (HR, 1.16; 95% CI, 1.06–1.26; P = .001)

Among patients receiving CAPOX, 3 months of therapy was like 6 months of therapy (HRDFS, 0.95; 95% CI, 0.85–1.06) and met the prespecified margin for noninferiority.

Among patients with N1 tumors (<4 positive nodes), the HR was 1.07 (0.97–1.17), and among those patients with N2 tumors (≥4 positive nodes), the HR was 1.07 (0.96–1.19).

Among patients with T4 tumors, a therapy duration of 3 months was inferior to a duration of 6 months (HR, 1.16; 95% CI, 1.03–1.31).

Among patients with low-risk tumors (T1–3, N1), 3 months of therapy was noninferior to 6 months of therapy (HR, 1.01; 95% CI, 0.90–1.12) with a 3-year DFS rate of 83.1% for patients who received 3 months of therapy and 83.3% for patients who received 6 months of therapy.

Among patients with high-risk tumors (T4 or N2), 6 months of therapy was superior to 3 months of therapy (HR, 1.12; 95% CI, 1.03–1.23; P = .01).

The IDEA study has generated much debate regarding the optimal length of therapy. It is recommended that patients and doctors weigh the pros and cons of potential diminished efficacy of 3 months of therapy versus the definite increased risk of toxicity, particularly neuropathy. CAPOX appears to be slightly more active than FOLFOX in the adjuvant setting.

Health professional

Treatment of Stage IV and Recurrent Colon Cancer

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Stage IV colon cancer denotes distant metastatic disease. Treatment of recurrent colon cancer depends on the sites of recurrent disease demonstrable by physical examination and/or radiographic studies. In addition to standard radiographic procedures, radioimmunoscintography may add clinical information that may affect management.[1] Such approaches have not led to improvements in long-term outcome measures such as survival.

Sources: 1

Treatment options for stage IV colon cancer, recurrent colon cancer, and liver metastases include:

Sources: stage IV colon cancer

Surgical resection of locally recurrent cancer.

Surgical resection and anastomosis or bypass of obstructing or bleeding primary lesions in selected metastatic cases.

Resection of liver metastases in selected metastatic patients (5-year cure rate for resection of solitary or combination metastases exceeds 20%) or ablation in selected patients.[2-11]

Sources: 2 · 11

Resection of isolated pulmonary or ovarian metastases in selected patients.[12]

Sources: 12

Palliative radiation therapy.

Palliative chemotherapy.

Targeted therapy.

Clinical trials comparing various new drugs, chemotherapy regimens, or biological therapies, alone or in combination.

Health professional · Treatment of Stage IV and Recurrent Colon Cancer

Treatment Options for Liver Metastasis

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Approximately 50% of colon cancer patients will be diagnosed with hepatic metastases, either at the time of initial presentation or because of disease recurrence. Although only a small proportion of patients with hepatic metastases are candidates for surgical resection, advances in tumor ablation techniques and in both regional and systemic chemotherapy administration provide for several treatment options. These include:

Surgery.

Sources: Surgery

Neoadjuvant chemotherapy.

Sources: Neoadjuvant chemotherapy

Local ablation.

Sources: Local ablation

Adjuvant chemotherapy.

Sources: Adjuvant chemotherapy

Intra-arterial chemotherapy.

Sources: Intra-arterial chemotherapy

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Liver Metastasis

Surgery

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Hepatic metastasis may be considered to be resectable based on the following factors:[5,7,13-16]

Sources: 5 · 7 · 13 · 16

Limited number of lesions.

Intrahepatic locations of lesions.

Lack of major vascular involvement.

Absent or limited extrahepatic disease.

Enough functional hepatic reserve.

For patients with resectable hepatic metastasis, a negative margin resection resulted in 5-year survival rates of 25% to 40% in mostly nonrandomized studies, such as the North Central Cancer Treatment Group trial (NCCTG-934653 [NCT00002575]).[5,7,13-16][Level of evidence C3] Improved surgical techniques and advances in preoperative imaging have improved patient selection for resection. In addition, multiple studies with multiagent chemotherapy have demonstrated that patients with metastatic disease isolated to the liver, which historically would be considered unresectable, can occasionally be made resectable after the administration of chemotherapy.[17]

Sources: NCCTG-934653 · 5 · 7 · 13 · 16 · Level of evidence C3 · 17

For patients with unresectable liver metastases, excellent outcomes have been achieved with liver transplant. The optimal patient cohort for this therapy is still being determined, but in general, the goal is to achieve good initial systemic control with chemotherapy, followed by transplant. In one study of 91 patients, 11% underwent live donor liver transplant. At a median follow-up of 1.5 years after transplant, the recurrence-free survival rate was 62% and the overall survival (OS) rate was 100%.[18][Level of evidence C3]

Sources: 18 · Level of evidence C3

In the TRANSMET study (NCT02597348), published in abstract form, 94 patients were randomly assigned to receive either chemotherapy and liver transplant (n = 47) or chemotherapy alone (n = 47). In an intent-to-treat analysis, the 5-year OS rate was 57% in the chemotherapy-and-liver transplant arm and 13% in the chemotherapy-alone arm. In a per-protocol analysis, the 5-year OS rate was 73% in the chemotherapy-and-liver transplant arm and 9% in the chemotherapy-alone arm.[19][Level of evidence A1]

Sources: TRANSMET · 19 · Level of evidence A1

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Liver Metastasis

Neoadjuvant chemotherapy for unresectable liver metastases

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Patients with hepatic metastases that are deemed unresectable will occasionally become candidates for resection if they have a good response to chemotherapy. These patients have 5-year survival rates similar to patients who initially had resectable disease.[17] There is no consensus on the best regimen to use to convert unresectable isolated liver metastases to resectable liver metastases.

Sources: 17

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Liver Metastasis

Local ablation

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Radiofrequency ablation has emerged as a safe technique (2% major morbidity and <1% mortality rate) that may provide for long-term tumor control.[20-26] Radiofrequency ablation and cryosurgical ablation [27-30] remain options for patients with tumors that cannot be resected and for patients who are not candidates for liver resection.

Sources: 20 · 26 · 27 · 30

Other local ablative techniques that have been used to manage liver metastases include embolization and interstitial radiation therapy.[31,32] Patients with limited pulmonary metastases, and patients with both pulmonary and hepatic metastases, may also be considered for surgical resection, with 5-year survival possible in highly-selected patients.[12,33,34]

Sources: 31 · 32 · 12 · 33 · 34

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Liver Metastasis

Adjuvant or neoadjuvant chemotherapy for resectable liver metastases

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

The role of adjuvant chemotherapy after potentially curative resection of liver metastases is uncertain.

Evidence (adjuvant or neoadjuvant chemotherapy for resectable liver metastases):

In the era before the use of FOLFOX (leucovorin calcium [LV], fluorouracil [5-FU], and oxaliplatin) and FOLFIRI (5-FU/LV/irinotecan), two trials attempted to randomly assign patients after resection of liver metastases to 5-FU/LV or observation, but both studies were closed early because of poor accrual.

The FFCD-9902 trial (NCT00304135) randomly assigned 173 patients (200 patients were planned) to postoperative 5-FU/LV, which is the Mayo Clinic regimen, or observation.[35]

Sources: FFCD-9902 · 35

The FFCD-9902 trial (NCT00304135) randomly assigned 173 patients (200 patients were planned) to postoperative 5-FU/LV, which is the Mayo Clinic regimen, or observation.[35]

The 5-year disease-free survival (DFS) rate was 33.5% for patients in the chemotherapy group and 26.7% for patients in the control group (Cox multivariate analysis: odds ratio (OR) for recurrence or death, 0.66; 95% confidence interval [CI], 0.46–0.96; P = .028). The 5-year OS rate was not significantly different between the groups (chemotherapy group, 51.1% vs. the control group, 41.1%; ORdeath, 0.73; 95% CI, 0.48–1.10; P = .13).

The European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada/Gruppo Interdisciplinare Valutazione Interventi in Oncologia (EORTC/NCIC/GIVIO) International trial attempted a similar random assignment of patients after surgical resection of liver metastases. The study closed because of poor accrual, and a combined analysis of the study and the FFCD-9902 study was done instead. In the combined analysis, 278 patients (138 of whom received chemotherapy; 14 of whom received surgery alone) were included.[36]

Sources: 36

The European Organisation for Research and Treatment of Cancer/National Cancer Institute of Canada/Gruppo Interdisciplinare Valutazione Interventi in Oncologia (EORTC/NCIC/GIVIO) International trial attempted a similar random assignment of patients after surgical resection of liver metastases. The study closed because of poor accrual, and a combined analysis of the study and the FFCD-9902 study was done instead. In the combined analysis, 278 patients (138 of whom received chemotherapy; 14 of whom received surgery alone) were included.[36]

The median progression-free survival (PFS) was 27.9 months in the chemotherapy arm and 18.8 months in the surgery alone arm (hazard ratio [HR], 1.32; 95% CI, 1.00–1.76; P = .058).

The median OS was 62.2 months in the chemotherapy arm compared with 47.3 months in the surgery-alone arm (HR, 1.32; 95% CI, 0.95–1.82; P = .095).

In the era of multiagent chemotherapy, two subsequent studies evaluated its role in the adjuvant setting following resection of liver metastases from colorectal cancer.

A phase III study randomly assigned 306 patients to 5-FU/LV or FOLFIRI after a resection of liver metastases.[37]

Sources: 37

A phase III study randomly assigned 306 patients to 5-FU/LV or FOLFIRI after a resection of liver metastases.[37]

There was no difference in DFS (21.6 months for 5-FU/LV vs. 24.7 months for FOLFIRI; HR, 0.89; log-rank P = .44) or OS (HR, 1.09; 95% CI, 0.72–1.64).

The EORTC-40983 trial (NCT00006479) randomly assigned 364 patients with up to four resectable liver metastases to perioperative FOLFOX (six cycles presurgery and six cycles postsurgery) or surgery alone.[38]

Sources: EORTC-40983 · 38

The EORTC-40983 trial (NCT00006479) randomly assigned 364 patients with up to four resectable liver metastases to perioperative FOLFOX (six cycles presurgery and six cycles postsurgery) or surgery alone.[38]

The PFS rate was 28.1% (95.66% CI, 21.3%–35.5%) for the surgery-alone group and 35.4% (28.1%–42.7%; HR, 0.79; 0.62–1.02; P = .058) for the perioperative chemotherapy group. There was no difference in OS. Subsequent post hoc analysis demonstrated that the difference in PFS in truly eligible patients rose 8.1% (from 28.1% [21.2%–36.6%] to 36.2% [28.7%–43.8%]; HR, 0.77 [0.60–1.00]; P = .041). In patients who underwent resection of liver metastases, the difference in PFS rose 9.2% (from 33.2% [25.3%–41.2%] to 42.4% [34.0%–50.5%]; HR, 0.73 [0.55–0.97]; P = .025).

Reversible postoperative complications occurred more often after chemotherapy than after surgery (40 [25%] of the 159 complications vs. 27 [16%] of the 170 complications; P = .04). After surgery, there were two deaths in the surgery-alone group and one in the perioperative chemotherapy group.

There is no high-level evidence to demonstrate that perioperative or postoperative chemotherapy improves OS for patients undergoing resection of liver metastases. Nevertheless, on the basis of post hoc subset analyses of the EORTC study, some physicians feel perioperative or postoperative therapy is reasonable in this setting.

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Liver Metastasis

Intra-arterial chemotherapy after liver resection

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Hepatic intra-arterial chemotherapy with floxuridine for liver metastases has produced higher overall response rates but no consistent improvement in survival when compared with systemic chemotherapy.[2,39-43] A meta-analysis of the randomized studies, which were all done in the era when only fluoropyrimidines were available for systemic therapy, did not demonstrate a survival advantage.[44]

Sources: 2 · 39 · 43 · 44

Evidence (intra-arterial chemotherapy after liver resection):

Two trials evaluated hepatic arterial floxuridine in the adjuvant setting after liver resection.

A trial of hepatic arterial floxuridine and dexamethasone plus systemic 5-FU/LV compared with systemic 5-FU/LV alone showed improved 2-year PFS rates (57% vs. 42%, P = .07) and OS rates (86% vs. 72%, P = .03) for patients in the combined therapy arm but did not show a significant statistical difference in median survival compared with systemic 5-FU therapy alone.[45][Level of evidence A1]

Sources: 45 · Level of evidence A1

A trial of hepatic arterial floxuridine and dexamethasone plus systemic 5-FU/LV compared with systemic 5-FU/LV alone showed improved 2-year PFS rates (57% vs. 42%, P = .07) and OS rates (86% vs. 72%, P = .03) for patients in the combined therapy arm but did not show a significant statistical difference in median survival compared with systemic 5-FU therapy alone.[45][Level of evidence A1]

The median survival in the combined therapy arm was 72.2 months versus 59.3 months in the monotherapy arm (P = .21).

A second trial preoperatively randomly assigned 109 patients who had one to three potentially resectable colorectal hepatic metastases to either no further therapy or postoperative hepatic arterial floxuridine plus systemic 5-FU.[46] Of those randomly assigned patients, 27% were deemed ineligible at the time of surgery, which left only 75 patients evaluable for recurrence and survival.

Sources: 46

A second trial preoperatively randomly assigned 109 patients who had one to three potentially resectable colorectal hepatic metastases to either no further therapy or postoperative hepatic arterial floxuridine plus systemic 5-FU.[46] Of those randomly assigned patients, 27% were deemed ineligible at the time of surgery, which left only 75 patients evaluable for recurrence and survival.

While liver cancer recurrence was decreased, median or 4-year survival was not significantly different between the patient groups.

Further studies are required to evaluate this treatment approach and to determine whether more effective systemic combination chemotherapy alone may provide similar results compared with hepatic intra-arterial therapy plus systemic treatment.

Several studies show increased local toxic effects with hepatic infusional therapy, including liver function abnormalities and fatal biliary sclerosis.

Health professional · Treatment of Stage IV and Recurrent Colon Cancer

Treatment Options for Stage IV and Recurrent Colon Cancer

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Treatment of patients with recurrent or advanced colon cancer depends on the location of the disease.

Surgery.

Sources: Surgery

Systemic therapy.

Sources: Systemic therapy

Immunotherapy.

Sources: Immunotherapy

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer

Surgery

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

For patients with locally recurrent and/or liver-only and/or lung-only metastatic disease, surgical resection, if feasible, is the only potentially curative treatment.

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer

Systemic therapy

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

The following drugs are used alone and in combination with other drugs for patients with metastatic colorectal cancer:

5-FU.

Sources: 5-FU

Capecitabine.

Sources: Capecitabine

Irinotecan.

Sources: Irinotecan

Oxaliplatin.

Sources: Oxaliplatin

Bevacizumab.

Sources: Bevacizumab

FOLFOXIRI (irinotecan, oxaliplatin, LV, and 5-FU).

Sources: FOLFOXIRI

Cetuximab.

Sources: Cetuximab

Ziv-aflibercept.

Sources: Ziv-aflibercept

Ramucirumab.

Sources: Ramucirumab

Panitumumab.

Sources: Panitumumab

Anti-epidermal growth factor receptor (EGFR) antibody versus anti-vascular endothelial growth factor (VEGF) antibody with first-line chemotherapy.

Sources: Anti-epidermal growth factor receptor (EGFR) antibody versus anti-vascular endothelial growth factor (VEGF) antibody with first-line chemotherapy

Trifluridine-tipiracil.

Sources: Trifluridine-tipiracil

Regorafenib.

Sources: Regorafenib

Fruquintinib.

Sources: Fruquintinib

Encorafenib with cetuximab for patients with BRAF V600E variants.

Sources: Encorafenib with cetuximab for patients with BRAF V600E variants

Sotorasib with panitumumab for patients with KRAS G12C variants.

Sources: Sotorasib with panitumumab for patients with KRAS G12C variants

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Systemic therapy

5-FU

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

When 5-FU was the only active chemotherapy drug, trials in patients with locally advanced, unresectable, or metastatic disease demonstrated partial responses and prolongation of the time-to-progression (TTP) of disease,[47,48] and improved survival and quality of life for patients who received chemotherapy versus best supportive care.[49-51] Several trials have analyzed the activity and toxic effects of various 5-FU/LV regimens using different doses and administration schedules and showed essentially equivalent results with a median survival time in the 12-month range.[52]

Sources: 47 · 48 · 49 · 51 · 52

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Systemic therapy

Capecitabine

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Before the advent of multiagent chemotherapy, two randomized studies demonstrated that capecitabine was associated with equivalent efficacy when compared with the Mayo Clinic regimen of 5-FU/LV.[53,54][Level of evidence A1]

Sources: 53 · 54 · Level of evidence A1

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Systemic therapy

Irinotecan

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Three randomized studies demonstrated improved response rates, PFS, and OS when irinotecan or oxaliplatin was combined with 5-FU/LV.[55-57]

Sources: 55 · 57

Evidence (irinotecan):

An intergroup study (NCCTG-N9741 [NCT00003594]) compared irinotecan/5-FU/LV (IFL) with oxaliplatin/LV/5-FU (FOLFOX-4) in first-line treatment for patients with metastatic colorectal cancer.

Sources: NCCTG-N9741

An intergroup study (NCCTG-N9741 [NCT00003594]) compared irinotecan/5-FU/LV (IFL) with oxaliplatin/LV/5-FU (FOLFOX-4) in first-line treatment for patients with metastatic colorectal cancer.

Patients assigned to FOLFOX-4 experienced an improved PFS (median, 6.9 months vs. 8.7 months; P = .014; HR, 0.74; 95% CI, 0.61–0.89) and OS (15.0 months vs. 19.5 months, P = .001; HR, 0.66; 95% CI, 0.54–0.82) compared with patients randomly assigned to IFL.

Subsequently, two studies compared FOLFOX with FOLFIRI, and patients were allowed to cross over upon progression on first-line therapy, respectively.[58,59][Level of evidence B1]

Sources: 58 · 59 · Level of evidence B1

Subsequently, two studies compared FOLFOX with FOLFIRI, and patients were allowed to cross over upon progression on first-line therapy, respectively.[58,59][Level of evidence B1]

PFS and OS were identical between the treatment arms in both studies.

The Bolus, Infusional, or Capecitabine with Camptosar-Celecoxib (BICC-C [NCT00094965]) trial evaluated several different irinotecan-based regimens in patients with previously untreated metastatic colorectal cancer, including FOLFIRI, irinotecan plus bolus 5-FU/LV (mIFL), and capecitabine/irinotecan (CAPIRI).[60][Level of evidence A1]

Sources: BICC-C · 60 · Level of evidence A1

The Bolus, Infusional, or Capecitabine with Camptosar-Celecoxib (BICC-C [NCT00094965]) trial evaluated several different irinotecan-based regimens in patients with previously untreated metastatic colorectal cancer, including FOLFIRI, irinotecan plus bolus 5-FU/LV (mIFL), and capecitabine/irinotecan (CAPIRI).[60][Level of evidence A1]

The study randomly assigned 430 patients and was closed early because of poor accrual.

The patients who received FOLFIRI had a better PFS than the patients who received either mIFL (7.6 months vs. 5.9 months, P = .004) or CAPIRI (7.6 months vs. 5.8 months, P = .015).

Patients who received CAPIRI had the highest grade 3 or higher rates of nausea, vomiting, diarrhea, dehydration, and hand-foot syndrome.

Since the publication of these studies, the use of either FOLFOX or FOLFIRI is considered acceptable for first-line treatment of patients with metastatic colorectal cancer.

When using an irinotecan-based regimen as first-line treatment of metastatic colorectal cancer, FOLFIRI is preferred.[60][Level of evidence B1]

Sources: 60 · Level of evidence B1

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Systemic therapy

Oxaliplatin

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Randomized phase III trials have addressed the equivalence of substituting capecitabine for infusional 5-FU. Two phase III studies have evaluated 5-FU/oxaliplatin (FUOX) versus capecitabine/oxaliplatin (CAPOX).[61,62]

Sources: 61 · 62

Evidence (oxaliplatin):

The AIO Colorectal Study Group randomly assigned 474 patients to either 5-FU/LV/oxaliplatin (FUFOX) or CAPOX.

The AIO Colorectal Study Group randomly assigned 474 patients to either 5-FU/LV/oxaliplatin (FUFOX) or CAPOX.

The median PFS was 7.1 months for the CAPOX arm and 8.0 months for the FUFOX arm (HR, 1.17; 95% CI, 0.96–1.43; P = .117), and the HR was in the prespecified equivalence range.

The Spanish Grupo de Tratamiento de los Tumores Digestivos randomly assigned 348 patients to CAPOX or FUOX.[61][Level of evidence B1]

Sources: 61 · Level of evidence B1

The Spanish Grupo de Tratamiento de los Tumores Digestivos randomly assigned 348 patients to CAPOX or FUOX.[61][Level of evidence B1]

The TTP was 8.9 months versus 9.5 months (P = .153) and met the prespecified range for noninferiority.

When using an oxaliplatin-based regimen as first-line treatment of metastatic colorectal cancer, a CAPOX regimen is not inferior to a FUOX regimen.

Before the availability of cetuximab, panitumumab, bevacizumab, and ziv-aflibercept as second-line therapy, second-line chemotherapy with irinotecan in patients treated with 5-FU/LV as first-line therapy demonstrated improved OS when compared with either infusional 5-FU or supportive care.[63-66]

Sources: 63 · 66

Similarly, a phase III trial randomly assigned patients who progressed on irinotecan and 5-FU/LV to bolus and infusional 5-FU/LV (LV5FU2), single-agent oxaliplatin, or FOLFOX-4. The median TTP for FOLFOX-4 versus LV5FU2 was 4.6 months versus 2.7 months (stratified log-rank test, 2-sided P < .001).[67][Level of evidence B1]

Sources: 67 · Level of evidence B1

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Systemic therapy

Bevacizumab

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Bevacizumab is a partially humanized monoclonal antibody that binds to VEGF. Bevacizumab can reasonably be added to either FOLFIRI or FOLFOX for patients undergoing first-line treatment of metastatic colorectal cancer.

Evidence (bevacizumab):

After bevacizumab was approved, the BICC-C trial was amended, and an additional 117 patients were randomly assigned to receive FOLFIRI/bevacizumab or mIFL/bevacizumab.

Sources: BICC-C

After bevacizumab was approved, the BICC-C trial was amended, and an additional 117 patients were randomly assigned to receive FOLFIRI/bevacizumab or mIFL/bevacizumab.

Although the primary end point of PFS was not significantly different, patients who received FOLFIRI/bevacizumab had a significantly better OS (not yet reached with a median follow-up of 22.6 months vs. 19.2 months, P = .007).

Patients with previously untreated metastatic colorectal cancer were randomly assigned to either IFL or IFL/bevacizumab.[68][Level of evidence A1]

Sources: 68 · Level of evidence A1

Patients with previously untreated metastatic colorectal cancer were randomly assigned to either IFL or IFL/bevacizumab.[68][Level of evidence A1]

The patients randomly assigned to IFL/bevacizumab experienced a significantly better PFS (10.6 months in the IFL/bevacizumab arm compared with 6.2 months in the IFL/placebo arm; HRdisease progression, 0.54; P < .001) and OS (20.3 months in the IFL/ bevacizumab arm compared with 15.6 months in the IFL/placebo arm; HRdeath , 0.66; P < .001).[68]

Sources: 68

Despite the lack of direct data, in standard practice, bevacizumab was added to FOLFOX as a standard first-line regimen based on the results of the NCCTG-N9741 trial.[69] Subsequently, in a randomized phase III study, patients with untreated, stage IV, colorectal cancer were randomly assigned in a 2 × 2 factorial design to CAPOX versus FOLFOX-4, then to bevacizumab versus placebo. PFS was the primary end point.

Sources: NCCTG-N9741 · 69

Despite the lack of direct data, in standard practice, bevacizumab was added to FOLFOX as a standard first-line regimen based on the results of the NCCTG-N9741 trial.[69] Subsequently, in a randomized phase III study, patients with untreated, stage IV, colorectal cancer were randomly assigned in a 2 × 2 factorial design to CAPOX versus FOLFOX-4, then to bevacizumab versus placebo. PFS was the primary end point.

In this trial, 1,401 patients were randomly assigned, and the median PFS was 9.4 months for patients who received bevacizumab and 8.0 months for the patients who received placebo (HR, 0.83; 97.5% CI, 0.72–0.95; P = .0023).[70][Level of evidence B1]

Sources: 70 · Level of evidence B1

The median OS was 21.3 months for patients who received bevacizumab and 19.9 months for patients who received placebo (HR, 0.89; 97.5% CI, 0.76–1.03; P = .077).

The median PFS (intention-to-treat analysis) was 8.0 months in the pooled CAPOX-containing arms versus 8.5 months in the FOLFOX-4-containing arms (HR, 1.04; 97.5% CI, 0.93–1.16), with the upper limit of the 97.5% CI being below the predefined noninferiority margin of 1.23.[70,71]

Sources: 70 · 71

The effect of bevacizumab on OS is likely to be less than what was seen in the original Hurwitz study.[68]

Sources: 68

Investigators from the Eastern Cooperative Oncology Group randomly assigned patients who had progressed on 5-FU/leucovorin and irinotecan to either FOLFOX or FOLFOX /bevacizumab.

Investigators from the Eastern Cooperative Oncology Group randomly assigned patients who had progressed on 5-FU/leucovorin and irinotecan to either FOLFOX or FOLFOX /bevacizumab.

Patients randomly assigned to FOLFOX/bevacizumab experienced a statistically significant improvement in PFS (7.43 months vs. 4.7 months, HR, 0.61; P < .0001) and OS (12.9 months vs. 10.8 months, HR, 0.75; P = .0011).[72][Level of evidence A1]

Sources: 72 · Level of evidence A1

Based on these studies, bevacizumab can reasonably be added to either FOLFIRI or FOLFOX for patients undergoing first-line treatment of metastatic colorectal cancer. A major question was whether the use of bevacizumab after first-line therapy was warranted when bevacizumab was used as a component of first-line therapy. At the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, data were presented from a randomized, controlled trial.[73] In the trial, 820 patients with metastatic colorectal cancer, after progressing on first-line chemotherapy that included bevacizumab, were randomly assigned to chemotherapy without bevacizumab or chemotherapy with bevacizumab. Patients who received bevacizumab experienced an improved OS compared with the patients who did not receive bevacizumab. The median OS was 11.2 months for patients who received bevacizumab/chemotherapy and 9.8 months for patients who received chemotherapy without bevacizumab (HR, 0.81; 95% CI, 0.69–0.94; unstratified log-rank test, P = .0062). The median PFS was 5.7 months for patients who received bevacizumab/chemotherapy and 4.1 months for those who received chemotherapy without bevacizumab (HR, 0.68; 95% CI, 0.59–0.78; unstratified log-rank test, P < .0001).[73][Level of evidence A1]

Sources: 73 · 73 · Level of evidence A1

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Systemic therapy

FOLFOXIRI

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Evidence (FOLFOXIRI):

The combination of FOLFOXIRI with bevacizumab was compared with FOLFIRI with bevacizumab in a randomized, phase III study of 508 patients with untreated metastatic colorectal cancer.[74][Level of evidence B1]

Sources: 74 · Level of evidence B1

The combination of FOLFOXIRI with bevacizumab was compared with FOLFIRI with bevacizumab in a randomized, phase III study of 508 patients with untreated metastatic colorectal cancer.[74][Level of evidence B1]

The median PFS was 12.1 months in the FOLFOXIRI group, compared with 9.7 months in the FOLFIRI group (HRprogression, 0.75; 95% CI, 0.62–0.90; P = .003). OS was not significantly different between the groups (31.0 vs. 25.8 months; HRdeath, 0.79; 95% CI, 0.63–1.00; P = .054).

Patients who received FOLFOXIRI had significantly more grade 3 and 4 toxicities, including neutropenia, stomatitis, and peripheral neuropathy.

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Systemic therapy

Cetuximab

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Cetuximab is a partially humanized monoclonal antibody against EGFR. Because cetuximab affects tyrosine kinase signaling at the surface of the cell membrane, tumors with activating variants of the pathway downstream of the EGFR, such as KRAS variants, are not sensitive to its effects. The addition of cetuximab to multiagent chemotherapy improves survival in patients with colon cancers that lack a KRAS variant (i.e., KRAS wild type). Importantly, patients with KRAS-altered tumors may experience worse outcome when cetuximab is added to multiagent chemotherapy regimens containing bevacizumab.

Evidence (cetuximab):

For patients who had disease progression while receiving irinotecan-containing regimens, a randomized phase II study was performed using either cetuximab or irinotecan and cetuximab.[75][Level of evidence C3]

Sources: 75 · Level of evidence C3

For patients who had disease progression while receiving irinotecan-containing regimens, a randomized phase II study was performed using either cetuximab or irinotecan and cetuximab.[75][Level of evidence C3]

The median TTP for patients who received cetuximab was 1.5 months, compared with the median TTP of 4.2 months for patients who received irinotecan/cetuximab.[75][Level of evidence B1]

Sources: 75 · Level of evidence B1

Based on this study, cetuximab was approved for use in patients with metastatic colorectal cancer refractory to 5-FU and irinotecan.

The Crystal Study (EMR 62202-013 [NCT00154102]) randomly assigned 1,198 patients with stage IV colorectal cancer to FOLFIRI with or without cetuximab.[76][Level of evidence B1]

Sources: EMR 62202-013 · 76 · Level of evidence B1

The Crystal Study (EMR 62202-013 [NCT00154102]) randomly assigned 1,198 patients with stage IV colorectal cancer to FOLFIRI with or without cetuximab.[76][Level of evidence B1]

The addition of cetuximab was associated with an improved PFS (HR, 0.85; 95% CI, 0.72–0.99; stratified log-rank P = .048) but not OS.

Retrospective studies of patients with metastatic colorectal cancer have suggested that responses to anti-EGFR antibody therapy are confined to patients with tumors that harbor wild types of KRAS (i.e., lack activating variants at codon 12 or 13 of the KRAS gene).

A subset analysis evaluating efficacy in relation to KRAS status was done in patients enrolled in the Crystal Study. There was a significant interaction for KRAS variant status and treatment for tumor response (P = .03) but not for PFS (P = .07). Among patients with KRAS wild-type tumors, the HR favored the FOLFIRI/cetuximab group (HR, 0.68; 95% CI, 0.50–0.94).

In a randomized trial, patients with metastatic colorectal cancer received capecitabine/oxaliplatin/bevacizumab with or without cetuximab.[77][Level of evidence B1]

Sources: 77 · Level of evidence B1

In a randomized trial, patients with metastatic colorectal cancer received capecitabine/oxaliplatin/bevacizumab with or without cetuximab.[77][Level of evidence B1]

The median PFS was 9.4 months in the group who received cetuximab and 10.7 months in the group who did not receive cetuximab (P = .01).

In a subset analysis, patients with tumors with KRAS variants who received cetuximab had significantly decreased PFS compared with patients with wild-type KRAS tumors who received cetuximab (8.1 months vs. 10.5 months; P = .04).

Among patients with KRAS-altered tumors, PFS was significantly shorter in those who received cetuximab than those did not receive cetuximab (8.1 months vs. 12.5 months; P = .003). OS was also significantly shorter (17.2 months vs. 24.9 months, respectively; P = .03).

The Medical Research Council (MRC) COIN trial (NCT00182715) sought to determine if adding cetuximab to combination chemotherapy with a fluoropyrimidine and oxaliplatin in first-line treatment for patients with KRAS wild-type tumors was beneficial.[78,79] In addition, the MRC sought to evaluate the effect of intermittent chemotherapy versus continuous chemotherapy. The 1,630 patients were randomly assigned to three treatment groups:The comparisons between arms A and B and arms A and C were analyzed and published separately.[78,79]

Sources: COIN · 78 · 79 · 78 · 79

The Medical Research Council (MRC) COIN trial (NCT00182715) sought to determine if adding cetuximab to combination chemotherapy with a fluoropyrimidine and oxaliplatin in first-line treatment for patients with KRAS wild-type tumors was beneficial.[78,79] In addition, the MRC sought to evaluate the effect of intermittent chemotherapy versus continuous chemotherapy. The 1,630 patients were randomly assigned to three treatment groups:The comparisons between arms A and B and arms A and C were analyzed and published separately.[78,79]

Arm A: fluoropyrimidine/oxaliplatin.

Arm B: fluoropyrimidine/oxaliplatin/cetuximab.

Arm C: intermittent fluoropyrimidine/oxaliplatin.

In patients with KRAS wild-type tumors (arm A, n = 367; arm B, n = 362), OS did not differ between treatment groups (median survival, 17.9 months [interquartile range (IQR) 10.3–29.2] in the control group vs. 17.0 months [IQR, 9.4–30.1] in the cetuximab group; HR, 1.04; 95% CI, 0.87–1.23; P = .67). Similarly, there was no effect on PFS (8.6 months [IQR, 5.0–12.5] in the control group versus 8.6 months [IQR, 5.1–13.8] in the cetuximab group; HR, 0.96; 95% CI, 0.82–1.12; P = .60).[78,79][Level of evidence A1]

Sources: 78 · 79 · Level of evidence A1

The reasons for lack of benefit in adding cetuximab are unclear. Subset analyses suggest that the use of capecitabine was associated with an inferior outcome, and the use of second-line therapy was less frequent in patients treated with cetuximab.

There was no difference between the continuously treated patients (arm A) and the intermittently treated patients (arm C). Median survival in the intent-to-treat population (n = 815 in both groups) was 15.8 months (IQR, 9.4–26.1) in arm A and 14.4 months (IQR, 8.0–24.7) in arm C (HR, 1.084; 80% CI, 1.008–1.165). In the per-protocol population, which included only those patients who were free from progression at 12 weeks and randomly assigned to continue treatment or go on a chemotherapy holiday (arm A, n = 467; arm C, n = 511), median survival was 19.6 months (IQR, 13.0–28.1) in arm A and 18.0 months (IQR, 12.1–29.3) in arm C (HR, 1.087; 95% CI, 0.986–1.198).

The upper limits of CIs for HRs in both analyses were greater than the predefined noninferiority boundary. While intermittent chemotherapy was not deemed noninferior, there appeared to be clinically insignificant differences in patient outcomes.

The OPUS study sought to evaluate the effect of adding cetuximab to first-line treatment with a FOLFOX regimen in an open-label, randomized, multicenter, phase II study of patients with EGFR-expressing metastatic colorectal cancer.[80]

Sources: 80

The OPUS study sought to evaluate the effect of adding cetuximab to first-line treatment with a FOLFOX regimen in an open-label, randomized, multicenter, phase II study of patients with EGFR-expressing metastatic colorectal cancer.[80]

In the trial, 344 patients were randomly assigned to receive FOLFOX-4 alone or FOLFOX-4/cetuximab. There was no statistically significant difference in response rate or PFS.

On subset analysis, patients with KRAS wild-type tumors were analyzed separately. In the KRAS wild-type tumor population, there was a statistically significant improvement in response rate (61% vs. 37%, P = .011) and PFS (7.7 months vs. 7.2 months, P = .0163).

On subset analysis among patients with KRAS-altered tumors, those who received FOLFOX-4/cetuximab had a statistically significant worse PFS than patients who received FOLFOX-4 alone (5.5 months vs. 8.6 months; P = .0192).[80][Level of evidence B1]

Sources: 80 · Level of evidence B1

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Systemic therapy

Ziv-aflibercept

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Ziv-aflibercept is an anti-VEGF molecule and has been evaluated as a component of second-line therapy in patients with metastatic colorectal cancer.

Evidence (ziv-aflibercept):

In one trial, 1,226 patients were randomly assigned to receive ziv-aflibercept (4 mg/kg intravenously [IV]) or placebo every 2 weeks in combination with FOLFIRI.[81][Level of evidence A2]

Sources: 81 · Level of evidence A2

In one trial, 1,226 patients were randomly assigned to receive ziv-aflibercept (4 mg/kg intravenously [IV]) or placebo every 2 weeks in combination with FOLFIRI.[81][Level of evidence A2]

Patients who received ziv-aflibercept/FOLFIRI had significantly improved OS rates, with median survival times of 13.50 months compared with patients who received placebo/FOLFIRI, with median survival times of 12.06 months (HR, 0.817; 95.34% CI, 0.713–0.937; P = .0032).

Patients who received ziv-aflibercept/FOLFIRI also had significantly improved PFS rates, with median PFS rates of 6.90 months compared with patients who received placebo/FOLFIRI, with median PFS rates of 4.67 months (HR, 0.758; 95% CI, 0.661–0.869; P < .0001).

Based on these results, the use of ziv-aflibercept/FOLFIRI is an acceptable second-line regimen for patients previously treated with FOLFOX-based chemotherapy. Whether to continue bevacizumab or initiate ziv-aflibercept in second-line therapy has not been addressed yet in any clinical trial, and there are no data available.

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Systemic therapy

Ramucirumab

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Ramucirumab is a fully humanized monoclonal antibody that binds to vascular endothelial growth factor receptor-2.

Evidence (ramucirumab):

In the randomized, unblinded, phase III RAISE study (NCT01183780), 1,072 patients with stage IV colorectal cancer who had progressed on first-line chemotherapy were randomly assigned to FOLFIRI with or without ramucirumab (8 mg/kg).[82][Level of evidence A1]

Sources: RAISE · 82 · Level of evidence A1

In the randomized, unblinded, phase III RAISE study (NCT01183780), 1,072 patients with stage IV colorectal cancer who had progressed on first-line chemotherapy were randomly assigned to FOLFIRI with or without ramucirumab (8 mg/kg).[82][Level of evidence A1]

Patients assigned to FOLFIRI/ramucirumab had a significant improvement in median OS (13.3 months vs. 11.7 months; HR, 0.84; P = .0219) and PFS (5.7 months vs. 4.5 months; HR, 0.793; P = .0005).

Grade 3 adverse events were more common in the ramucirumab group, including grade 3 neutropenia.

Based on these data, FOLFIRI/ramucirumab is an acceptable second-line regimen for patients previously treated with FOLFOX/bevacizumab. Whether to continue bevacizumab in second-line chemotherapy or use ramucirumab in second-line chemotherapy has not yet been addressed in a clinical trial.

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Systemic therapy

Panitumumab

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Panitumumab is a fully humanized antibody against the EGFR. The U.S. Food and Drug Administration (FDA) approved panitumumab for patients with metastatic colorectal cancer refractory to chemotherapy.[83] In clinical trials, panitumumab demonstrated efficacy as a single agent or in combination therapy, which was consistent with the effects on PFS and OS with cetuximab. There appears to be a consistent class effect.

Sources: panitumumab · 83

Evidence (panitumumab):

In a phase III trial, patients with chemotherapy-refractory colorectal cancer were randomly assigned to panitumumab or best supportive care.[83][Level of evidence B1]

Sources: 83 · Level of evidence B1

In a phase III trial, patients with chemotherapy-refractory colorectal cancer were randomly assigned to panitumumab or best supportive care.[83][Level of evidence B1]

Patients who received panitumumab experienced an improved PFS (8 weeks vs. 7.3 weeks; HR, 0.54; 95% CI, 0.44–0.66; P < .0001).

There was no difference in OS, which was thought to be the result of 76% of patients on best supportive care crossing over to panitumumab.

In the Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy (PRIME) study [NCT00364013], 1,183 patients were randomly assigned to FOLFOX-4 with or without panitumumab as first-line therapy for metastatic colorectal cancer. The study was amended to enlarge the sample size to address patients with the KRAS wild-type tumors and patients with KRAS-altered tumors separately.[84][Level of evidence B1]

Sources: PRIME · 84 · Level of evidence B1

In the Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy (PRIME) study [NCT00364013], 1,183 patients were randomly assigned to FOLFOX-4 with or without panitumumab as first-line therapy for metastatic colorectal cancer. The study was amended to enlarge the sample size to address patients with the KRAS wild-type tumors and patients with KRAS-altered tumors separately.[84][Level of evidence B1]

For patients with KRAS wild-type tumors, a statistically significant improvement in PFS was observed in those who received panitumumab/FOLFOX-4 compared with those who received only FOLFOX-4 (HR, 0.80; 95% CI, 0.66–0.97; stratified log-rank P = .02).

The median PFS was 9.6 months (95% CI, 9.2–11.1) for patients who received panitumumab/FOLFOX-4 and 8.0 months (95% CI, 7.5–9.3) for patients who received FOLFOX-4. OS was not significantly different between the groups (HR, 0.83; 95% CI, 0.67–1.02; P = .072).

For patients with KRAS-altered tumors, there was worse PFS with the addition of panitumumab (HR, 1.29; 95% CI, 1.04–1.62; stratified log-rank P = .02).

In the Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy (PRIME) study [NCT00364013], 1,183 patients were randomly assigned to FOLFOX-4 with or without panitumumab as first-line therapy for metastatic colorectal cancer. The study was amended to enlarge the sample size to address patients with the KRAS wild-type tumors and patients with KRAS-altered tumors separately.[84][Level of evidence B1] › For patients with KRAS-altered tumors, there was worse PFS with the addition of panitumumab (HR, 1.29; 95% CI, 1.04–1.62; stratified log-rank P = .02).

The median PFS was 7.3 months (95% CI, 6.3–8.0) for panitumumab/FOLFOX-4 and 8.8 months (95% CI, 7.7–9.4) for FOLFOX-4 alone.

In the Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy (PRIME) study [NCT00364013], 1,183 patients were randomly assigned to FOLFOX-4 with or without panitumumab as first-line therapy for metastatic colorectal cancer. The study was amended to enlarge the sample size to address patients with the KRAS wild-type tumors and patients with KRAS-altered tumors separately.[84][Level of evidence B1]

Subsequently, a retrospective analysis evaluated patients with wild-type KRAS exon 2 status for other KRAS and BRAF variants.[85][Level of evidence C1]

Sources: 85 · Level of evidence C1

In the Panitumumab Randomized Trial in Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy (PRIME) study [NCT00364013], 1,183 patients were randomly assigned to FOLFOX-4 with or without panitumumab as first-line therapy for metastatic colorectal cancer. The study was amended to enlarge the sample size to address patients with the KRAS wild-type tumors and patients with KRAS-altered tumors separately.[84][Level of evidence B1] › Subsequently, a retrospective analysis evaluated patients with wild-type KRAS exon 2 status for other KRAS and BRAF variants.[85][Level of evidence C1]

Of the 620 patients who were initially identified as not having a variant in exon 2 of KRAS, 108 patients (17%) were found to have additional RAS variants and 53 patients (8%) were found to have BRAF variants. In a retrospective analysis, patients without any RAS or BRAF variants had a longer PFS (10.8 months vs. 9.2 months, P = .002) and OS (28.3 months vs. 20.9 months, P = .02) when assigned to the FOLFOX-4/panitumumab arm than the patients assigned to the FOLFOX-4 arm.

Similarly, the addition of panitumumab to a regimen of FOLFOX/bevacizumab resulted in a worse PFS and worse toxicity compared with a regimen of FOLFOX/bevacizumab alone in patients not selected for KRAS variant in metastatic colon cancer (11.4 months vs. 10.0 months, HR, 1.27; 95% CI, 1.06–1.52).[86][Level of evidence B1]

Sources: 86 · Level of evidence B1

In another study (NCT00339183), patients with metastatic colorectal cancer who had already received a fluoropyrimidine regimen were randomly assigned to either FOLFIRI or FOLFIRI/panitumumab.[87][Level of evidence B1]

Sources: NCT00339183 · 87 · Level of evidence B1

In another study (NCT00339183), patients with metastatic colorectal cancer who had already received a fluoropyrimidine regimen were randomly assigned to either FOLFIRI or FOLFIRI/panitumumab.[87][Level of evidence B1]

In a post hoc analysis, patients with KRAS wild-type tumors experienced a statistically significant PFS advantage (HR, 0.73; 95% CI, 0.59–0.90; stratified log-rank P = .004).

In another study (NCT00339183), patients with metastatic colorectal cancer who had already received a fluoropyrimidine regimen were randomly assigned to either FOLFIRI or FOLFIRI/panitumumab.[87][Level of evidence B1] › In a post hoc analysis, patients with KRAS wild-type tumors experienced a statistically significant PFS advantage (HR, 0.73; 95% CI, 0.59–0.90; stratified log-rank P = .004).

The median PFS was 5.9 months (95% CI, 5.5–6.7) for panitumumab/FOLFIRI and 3.9 months (95% CI, 3.7–5.3) for FOLFIRI alone.

In another study (NCT00339183), patients with metastatic colorectal cancer who had already received a fluoropyrimidine regimen were randomly assigned to either FOLFIRI or FOLFIRI/panitumumab.[87][Level of evidence B1]

OS was not significantly different. Patients with KRAS-altered tumors experienced no benefit from the addition of panitumumab.

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Systemic therapy

Anti-EGFR antibody versus anti-VEGF antibody with first-line chemotherapy

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

In the management of patients with stage IV colorectal cancer, it is unknown whether patients with KRAS wild-type cancer should receive an anti-EGFR antibody with chemotherapy or an anti-VEGF antibody with chemotherapy. Two studies attempted to answer this question.[88,89]

Sources: 88 · 89

Evidence (anti-EGFR antibody vs. anti-VEGF antibody with first-line chemotherapy)

The FIRE-3 study (NCT00433927) randomly assigned 592 patients with KRAS exon 2 wild-type tumors who were previously untreated to FOLFIRI/cetuximab (297 patients) or FOLFIRI/bevacizumab (295 patients). The primary end point of the study was objective response rate.[88][Level of evidence A1]

Sources: FIRE-3 · 88 · Level of evidence A1

The FIRE-3 study (NCT00433927) randomly assigned 592 patients with KRAS exon 2 wild-type tumors who were previously untreated to FOLFIRI/cetuximab (297 patients) or FOLFIRI/bevacizumab (295 patients). The primary end point of the study was objective response rate.[88][Level of evidence A1]

The objective response rate was not significantly different between the groups (objective response rate, 62.0%; 95% CI, 56.2%–67.5% vs. objective response rate, 58.0%; 95% CI, 52.1%–63.7%; OR, 1.18; 95% CI, 0.85–1.64; P = .18).

The median PFS was 10.0 months (95% CI, 8.8–10.8) in the cetuximab group and 10.3 months (95% CI, 9.8–11.3) in the bevacizumab group (HR, 1.06; 95% CI, 0.88–1.26; P = .55).

The median OS was 28.7 months (95% CI, 24.0–36.6) in the cetuximab group compared with 25.0 months (22.7–27.6) in the bevacizumab group (HR, 0.77; 95% CI, 0.62–0.96; P = .017).

In a post hoc analysis of patients with expanded RAS wild-type tumors (sequencing for mutational hot spots within KRAS and NRAS genes, including exon 2 codons 12 and 13; exon 3 codons 59 and 61; and exon 4 codons 117 and 146), the median OS was 33.1 months (95% CI, 24.5–39.4) in the cetuximab group compared with 25.0 months (95% CI, 23.0–28.1) in the bevacizumab group (HR, 0.70; 95% CI, 0.54–0.90; P = .0059).[90]

Sources: 90

Of note, only 52% of patients assigned to the bevacizumab arm subsequently received cetuximab or panitumumab.[91]

Sources: 91

The Cancer and Leukemia Group B Intergroup study 80405 (NCT00265850) was presented at the ASCO meeting in 2014. This study randomly assigned 2,334 previously untreated patients with KRAS wild-type cancer to chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab or chemotherapy/cetuximab. OS was the primary end point.[89][Level of evidence B1]

Sources: Intergroup study 80405 · 89 · Level of evidence B1

The Cancer and Leukemia Group B Intergroup study 80405 (NCT00265850) was presented at the ASCO meeting in 2014. This study randomly assigned 2,334 previously untreated patients with KRAS wild-type cancer to chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab or chemotherapy/cetuximab. OS was the primary end point.[89][Level of evidence B1]

There was no statistically significant difference in OS among the patients assigned to bevacizumab or cetuximab (for OS differences, chemotherapy/bevacizumab = 29.04 [25.66–31.21] months vs. chemotherapy/cetuximab = 29.93 [27.56–31.21] months; HR, 0.92 [0.78–1.09]; P = .34).

Based on these two studies, no apparent significant difference is evident about starting treatment with chemotherapy/bevacizumab or chemotherapy/cetuximab in patients with KRAS wild-type metastatic colorectal cancer. However, in patients with KRAS wild-type cancer, administration of an anti-EGFR antibody during management improves OS.

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Systemic therapy

Trifluridine-tipiracil

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Trifluridine-tipiracil (Lonsurf; also called TAS-102) is an orally administered combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. Trifluridine, in its triphosphate form, inhibits thymidylate synthase; therefore, trifluridine, in this form, has an antitumor effect. Tipiracil hydrochloride is a potent inhibitor of thymidine phosphorylase, which actively degrades trifluridine. The combination of trifluridine and tipiracil allows for adequate plasma levels of trifluridine.

Sources: Lonsurf

Evidence (trifluridine-tipiracil):

A phase III, double-blind study (RECOURSE [NCT01607957]) randomly assigned 800 stage IV colorectal cancer patients whose cancer had been refractory to two previous therapies. Patients were required to have received 5-FU, oxaliplatin, irinotecan, bevacizumab and, if the patients had KRAS wild-type cancer, cetuximab or panitumumab. Patients were randomly assigned in a 2:1 ratio to receive best supportive care plus trifluridine-tipiracil (n = 534) or placebo (n = 266). The median age of patients was 63 years, and most patients (60%–63%) received four or more previous lines of therapy. All patients had formerly received fluoropyrimidine, irinotecan, oxaliplatin, and bevacizumab, and 52% of them had received an EGFR inhibitor. Approximately 20% of the patients had received previous treatment with regorafenib.[92][Level of evidence A1]

Sources: RECOURSE · 92 · Level of evidence A1

A phase III, double-blind study (RECOURSE [NCT01607957]) randomly assigned 800 stage IV colorectal cancer patients whose cancer had been refractory to two previous therapies. Patients were required to have received 5-FU, oxaliplatin, irinotecan, bevacizumab and, if the patients had KRAS wild-type cancer, cetuximab or panitumumab. Patients were randomly assigned in a 2:1 ratio to receive best supportive care plus trifluridine-tipiracil (n = 534) or placebo (n = 266). The median age of patients was 63 years, and most patients (60%–63%) received four or more previous lines of therapy. All patients had formerly received fluoropyrimidine, irinotecan, oxaliplatin, and bevacizumab, and 52% of them had received an EGFR inhibitor. Approximately 20% of the patients had received previous treatment with regorafenib.[92][Level of evidence A1]

Trifluridine-tipiracil was administered at 35 mg/m2 twice daily with meals for 5 days, with 2 days of rest for 2 weeks, followed by a 14-day rest period.

The primary end point of the study was OS. The median OS for patients with metastatic colorectal cancer who received trifluridine-tipiracil was 7.1 months compared with 5.3 months for those who received a placebo (HR, 0.68; P < .0001).

The median PFS time in the trifluridine-tipiracil arm was 2 months versus 1.7 months with a placebo (HR, 0.48; P < .0001).

Secondary end points focused on PFS, overall response rate, and disease control rate.

The overall response rate was 1.6% with trifluridine-tipiracil, which consisted of a complete response in one patient and partial responses in other patients. The overall response rate with a placebo was 0.4% (P = .29).

The FDA approved trifluridine-tipiracil for the treatment of patients with metastatic colorectal cancer, based on the results of the RECOURSE trial.

Evidence (combination of trifluridine-tipiracil and bevacizumab):

A phase III, international, multi-institutional trial (SUNLIGHT [NCT04737187]) included 492 patients with stage IV colorectal cancer whose cancer was refractory to up to two prior chemotherapy regimens. Patients were required to have received 5-FU, oxaliplatin, irinotecan, an anti-VEGF monoclonal antibody, or an anti-EGFR monoclonal antibody (for patients with RAS wild-type disease). Patients were randomly assigned 1:1 to receive either trifluridine-tipiracil monotherapy (n = 246) or trifluridine-tipiracil combined with bevacizumab (n = 246). The median patient age was 62 years for the combination arm, and 64 years for the monotherapy arm and most patients (93% and 91%) had received two prior lines of therapy. Over 98% of patients in both arms had received 5-FU, irinotecan, and oxaliplatin, and over 93% of patients with RAS wild-type variants in both arms had received anti-EGFR monoclonal antibody therapy. The median follow-up was 14.2 months. Trifluridine-tipiracil was given at 35 mg/m2 twice daily on days 1 to 5 and 8 to 12 of a 28-day cycle. Bevacizumab was given on days 1 and 15 of each cycle at 5 mg/kg. The primary end point of the study was OS.[93]

Sources: SUNLIGHT · 93

A phase III, international, multi-institutional trial (SUNLIGHT [NCT04737187]) included 492 patients with stage IV colorectal cancer whose cancer was refractory to up to two prior chemotherapy regimens. Patients were required to have received 5-FU, oxaliplatin, irinotecan, an anti-VEGF monoclonal antibody, or an anti-EGFR monoclonal antibody (for patients with RAS wild-type disease). Patients were randomly assigned 1:1 to receive either trifluridine-tipiracil monotherapy (n = 246) or trifluridine-tipiracil combined with bevacizumab (n = 246). The median patient age was 62 years for the combination arm, and 64 years for the monotherapy arm and most patients (93% and 91%) had received two prior lines of therapy. Over 98% of patients in both arms had received 5-FU, irinotecan, and oxaliplatin, and over 93% of patients with RAS wild-type variants in both arms had received anti-EGFR monoclonal antibody therapy. The median follow-up was 14.2 months. Trifluridine-tipiracil was given at 35 mg/m2 twice daily on days 1 to 5 and 8 to 12 of a 28-day cycle. Bevacizumab was given on days 1 and 15 of each cycle at 5 mg/kg. The primary end point of the study was OS.[93]

The median OS was 10.8 months for patients who received trifluridine-tipiracil and bevacizumab and 7.5 months for patients who received trifluridine-tipiracil monotherapy (HR, 0.61; 95% CI, 0.49–0.77; P < .001).[93][Level of evidence A1]

Sources: 93 · Level of evidence A1

OS was significant across subgroups, including patients with RAS variants and wild-type variants, patients with microsatellite instability-high (MSI-H) and microsatellite stability (MSS) cancers, and both for patients previously treated with bevacizumab and bevacizumab-naïve patients.

The median PFS was 5.6 months in the combination arm and 2.4 months in the trifluridine-tipiracil monotherapy arm (HR, 0.44; 95% CI, 0.36–0.54; P < .001).

Secondary end points focused on PFS, overall response rate, and safety.

The overall response rate was 6.1% for the combination arm and 1.2% for the monotherapy arm.

Adverse events leading to therapy discontinuation were observed in 12.6% of patients in both arms. Dose reductions occurred in 16.3% of patients in the combination group and 12.2% of patients in the trifluridine-tipiracil monotherapy group. The most common adverse event was neutropenia, with grade 3 or 4 neutropenia observed in 43% of patients in the combination arm and 32% of patients in the monotherapy arm.

The FDA approved the combination of trifluridine-tipiracil and bevacizumab for the treatment of patients with previously treated metastatic colorectal cancer based on the results of the SUNLIGHT trial.

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Systemic therapy

Regorafenib

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Regorafenib is an inhibitor of multiple tyrosine kinase pathways, including VEGF. In 2012, the FDA approved regorafenib for patients who had progressed on previous therapy.

Evidence (regorafenib):

The safety and effectiveness of regorafenib were evaluated in a single, clinical study of 760 patients with previously treated metastatic colorectal cancer. Patients were randomly assigned 2:1 to receive regorafenib or a placebo in addition to the best supportive care.[94,95]

Sources: 94 · 95

The safety and effectiveness of regorafenib were evaluated in a single, clinical study of 760 patients with previously treated metastatic colorectal cancer. Patients were randomly assigned 2:1 to receive regorafenib or a placebo in addition to the best supportive care.[94,95]

Patients treated with regorafenib had a statistically significant improvement in OS (6.4 months in the regorafenib group vs. 5.0 months in the placebo group; HR, 0.77; 95% CI, 0.64–0.94; one-sided P = .0052).

With the improved OS from the combination of trifluridine-tipiracil and bevacizumab discussed above, regorafenib is now often considered a fourth-line or later option for treatment of patients with metastatic colorectal cancer.

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Systemic therapy

Fruquintinib

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Fruquintinib is an inhibitor of VEGF receptors 1, 2 and 3. In 2023, the FDA approved fruquintinib for adults with metastatic colorectal cancer who had previously received fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy and an anti-VEGF therapy. If patients had RAS wild-type disease and were medically appropriate, an anti-EGFR therapy was also required.

Evidence (fruquintinib):

The phase III, international, double-blind, placebo-controlled FRESCO-2 trial (NCT04322539) included 691 patients with metastatic colorectal adenocarcinoma who had received all standard approved cytotoxic and targeted therapies. Patients had disease progression during, or were intolerant of, trifluridine-tipiracil, regorafenib, or both. Patients had received a median of four lines of prior systemic therapy. Patients were randomly assigned in a 2:1 fashion to receive one of the following regimens: All patients received best supportive care. A total of 461 patients received fruquintinib, and 230 received placebo. The primary end point was OS.[96] The results were as follows:

Sources: FRESCO-2 · 96

The phase III, international, double-blind, placebo-controlled FRESCO-2 trial (NCT04322539) included 691 patients with metastatic colorectal adenocarcinoma who had received all standard approved cytotoxic and targeted therapies. Patients had disease progression during, or were intolerant of, trifluridine-tipiracil, regorafenib, or both. Patients had received a median of four lines of prior systemic therapy. Patients were randomly assigned in a 2:1 fashion to receive one of the following regimens: All patients received best supportive care. A total of 461 patients received fruquintinib, and 230 received placebo. The primary end point was OS.[96] The results were as follows:

Fruquintinib (5 mg orally once daily on days 1–21 of a 28-day cycle).

Placebo (orally once daily on days 1–21 of a 28-day cycle).

The median OS was significantly longer in the fruquintinib group (7.4 months; 95% CI, 6.7–8.2) than in the placebo group (4.8 months; 95% CI, 4.0–5.8) (HR, 0.66; 95% CI, 0.55–0.80; P < .0001).[96][Level of evidence A1]

Sources: 96 · Level of evidence A1

The median PFS was 3.7 months (95% CI, 3.5–3.8) in the fruquintinib group and 1.8 months (95% CI, 1.8–1.9) in the placebo group (HR, 0.26; 95% CI, 0.21–0.34; P < .001).

Subgroup analyses demonstrated the benefit of fruquintinib as opposed to placebo in most subgroups. Notably, this benefit was seen in patients with both RAS variants and RAS wild-type disease, patients with liver metastases, and patients pretreated with trifluridine-tipiracil with or without regorafenib.

The disease control rate was significantly longer in the fruquintinib group (56%) than in the placebo group (16%), with an adjusted difference of 39% (95% CI, 32.8%–46.0%; P < .0001).

Grade 3 or higher adverse events occurred in 65% of patients in the fruquintinib group. The most common adverse events were hypertension (14%), asthenia (8%), abnormal hepatic function (8%), dermatologic toxicity (7%), and hand-foot syndrome (6%). Grade 3 or higher adverse events occurred in 50% of patients in the placebo group. The most common were abnormal hepatic function (9%), infection (6%), and asthenia (4%).

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Systemic therapy

Encorafenib with cetuximab in patients with BRAF V600E variants

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

BRAF V600E variants occur in about 10% of metastatic colorectal cancers and are an indicator of poor prognosis. Unlike in melanoma, BRAF inhibitor monotherapy has not shown a benefit in colorectal cancer, and multiple studies have evaluated concurrent targeting of the EGFR-MAPK pathway.

Evidence (encorafenib with cetuximab in patients with BRAF V600E variants):

Encorafenib (BRAF inhibitor), binimetinib (MEK inhibitor), and cetuximab (EGFR inhibitor): In the international, open-label, randomized, phase III BEACON trial, patients with metastatic colorectal cancer and BRAF V600E variants who previously received one or two treatment regimens were enrolled.[97] The trial randomly assigned 665 patients in a 1:1:1 ratio to receive one of the following: The primary end points were OS and objective response in the triplet-therapy group when compared with the control group.Updated data were presented in abstract form in 2020:[98]

Sources: BEACON · 97 · 98

Encorafenib (BRAF inhibitor), binimetinib (MEK inhibitor), and cetuximab (EGFR inhibitor): In the international, open-label, randomized, phase III BEACON trial, patients with metastatic colorectal cancer and BRAF V600E variants who previously received one or two treatment regimens were enrolled.[97] The trial randomly assigned 665 patients in a 1:1:1 ratio to receive one of the following: The primary end points were OS and objective response in the triplet-therapy group when compared with the control group.Updated data were presented in abstract form in 2020:[98]

Triplet therapy: encorafenib (300 mg PO daily), binimetinib (45 mg PO twice daily), and cetuximab (400 mg/m2 IV loading dose followed by 250 mg/m2 IV weekly) (n = 224).

Doublet therapy: encorafenib and cetuximab (as per triplet therapy dosing) (n = 220).

Control group: FOLFIRI or irinotecan (every 2 weeks) with cetuximab (400 mg/m2 IV loading dose followed by 250 mg/m2 IV weekly) (n = 221).

The OS was 9.0 months in the triplet-therapy arm and 5.4 months in the control group (HR, 0.52; 95% CI, 0.39–0.70, P < .0001).[97][Level of evidence A1]

Sources: 97 · Level of evidence A1

Grade 3 or higher side effects occurred in 58% of patients in the triplet-therapy arm, with 10% of patients experiencing diarrhea and 11% of patients experiencing anemia. Grade 3 or higher side effects occurred in 50% of patients in the doublet-therapy arm and 61% of patients in the control arm. Fourteen percent of patients who received the doublet regimen developed melanocytic nevi.

The median OS was 9.3 months in both the triplet-therapy and doublet-therapy arms and 5.9 months in the control arm (HR, 0.60 for triplet therapy vs. control; 95% CI, 0.47–0.75; HR, 0.61 for doublet therapy vs. control; 95% CI, 0.48–0.77).

The objective response rate was 26.8% for patients who received triplet therapy (95% CI, 21.1%–33.1%) and 19.5% for patients who received doublet therapy (95% CI, 14.5%–25.4%).

Based on these data, the FDA approved the combination of encorafenib with cetuximab for patients with previously treated metastatic colon cancer and BRAF V600E variants.

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Systemic therapy

Sotorasib with panitumumab for patients with KRAS G12C variants

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

KRAS G12C variants are found in approximately 4% of patients with colorectal cancer and are associated with poor prognosis.[99-102] Sotorasib and adagrasib are two of the first KRAS G12C–specific inhibitors to show benefit in patients with KRAS G12C–altered cancers.[103,104] Given that EGFR reactivation is a well-described resistance mechanism to KRAS G12C inhibition, sotorasib was combined with the anti-EGFR antibody panitumumab in patients with colorectal cancer and KRAS G12C variants.

Sources: 99 · 102 · 103 · 104

The phase III, multicenter, open-label CodeBreaK 300 trial (NCT05198934) included patients with metastatic colorectal cancer and KRAS G12C variants who previously received treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.[103] The trial randomly assigned 160 patients 1:1:1 to receive one of the following:The primary end point was PFS assessed by blinded independent central review according to RECIST 1.1. Secondary end points included OS and objective response rate.

Sources: CodeBreaK 300 · 103

The phase III, multicenter, open-label CodeBreaK 300 trial (NCT05198934) included patients with metastatic colorectal cancer and KRAS G12C variants who previously received treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.[103] The trial randomly assigned 160 patients 1:1:1 to receive one of the following:The primary end point was PFS assessed by blinded independent central review according to RECIST 1.1. Secondary end points included OS and objective response rate.

Doublet therapy with sotorasib 960 mg once daily plus panitumumab (6 mg/kg IV every 2 weeks) (n = 53).

Doublet therapy with sotorasib 240 mg once daily plus panitumumab (6 mg/kg IV every 2 weeks) (n = 53).

Investigator's choice standard-of-care therapy with trifluridine-tipiracil (35 mg/m2) or regorafenib (160 mg once daily) (control group).

The median PFS was 5.6 months (95% CI, 4.2–6.3) in the 960 mg-sotorasib/panitumumab group, 3.9 months (95% CI, 3.7–5.8) in the 240 mg-sotorasib/panitumumab group, and 2.2 months (95% CI, 1.9–3.9) in the standard-of-care group.[103][Level of evidence B1]

Sources: 103 · Level of evidence B1

The HR for progression of disease or death was 0.49 (95% CI, 0.3–0.8; P = .006) for the 960 mg-sotorasib/panitumumab group and 0.58 (95% CI, 0.36–0.98; P = .03) for the 240 mg-sotorasib/panitumumab group.

The objective response rate was 26.4% (95% CI, 15.3%–40.3%) in the 960 mg-sotorasib/panitumumab group, 5.7% (95% CI, 1.2%–15.7%) in the 240 mg-sotorasib/panitumumab group, and 0% (95% CI, 0.0%–6.6%) in the standard-of-care group. OS data are still not mature. However, at data cutoff the HRs were 0.77 (95% CI, 0.4–1.45) for the 960 mg-sotorasib/panitumumab group and 0.91 (95% CI, 0.48–1.71) for the 240 mg-sotorasib/panitumumab group when compared with standard-of-care therapy.

Grade 3 or higher side effects occurred in 35.8% of patients who received 960 mg sotorasib/panitumumab, 30.2% of patients who received 240 mg sotorasib/panitumumab, and 43.1% of patients who received the standard of care. The most common adverse effects with combined sotorasib and panitumumab therapy were skin-related toxicities and hypomagnesemia.

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer

Immunotherapy

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Approximately 4% of patients with stage IV colorectal cancer have tumors that are mismatch repair deficient (dMMR) or microsatellite unstable/MSI-H. The MSI-H phenotype is associated with germline defects in the MLH1, MSH2, MSH6, and PMS2 genes and is the primary phenotype observed in tumors from patients with hereditary nonpolyposis colorectal cancer (HNPCC) or Lynch syndrome. Patients can also have the MSI-H phenotype because one of these genes was silenced via DNA methylation. Testing for microsatellite instability can be done with molecular genetic tests, which look for microsatellite instability in the tumor tissue, or with immunohistochemistry, which looks for the loss of mismatch repair proteins. MSI-H status has historically been prognostic of increased survival for patients with earlier-stage disease and since 2015, has also been found to predict tumor response to checkpoint inhibition.

The FDA approved pembrolizumab for patients with treatment-naïve, metastatic, dMMR/MSI-H colorectal cancer in 2020. Studies regarding first-line treatment with dual checkpoint inhibitors are ongoing. The FDA approved the anti-programmed cell death protein 1 (PD-1) antibodies pembrolizumab and nivolumab in 2017 for patients with microsatellite-unstable tumors who had previously received 5-FU, oxaliplatin, and irinotecan-based therapy. In 2018, the FDA granted accelerated approval for the combination of nivolumab with ipilimumab (a CTLA-4 inhibitor) to treat MSI-H colorectal cancers that progressed on prior 5-FU, oxaliplatin, and irinotecan-based therapies.

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Immunotherapy

First-line immunotherapy

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Immunotherapy / First-line immunotherapy

Pembrolizumab monotherapy

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Evidence (pembrolizumab monotherapy):

In the phase III, open-label, international, randomized KEYNOTE-177 trial (NCT02563002), 307 patients with treatment-naïve MSI-H or dMMR metastatic colorectal cancer were randomly assigned in a 1:1 ratio to receive either pembrolizumab (200 mg every 3 weeks) or chemotherapy (FOLFIRI or modified FOLFOX-6 with or without bevacizumab or cetuximab).[105]

Sources: KEYNOTE-177 · 105

In the phase III, open-label, international, randomized KEYNOTE-177 trial (NCT02563002), 307 patients with treatment-naïve MSI-H or dMMR metastatic colorectal cancer were randomly assigned in a 1:1 ratio to receive either pembrolizumab (200 mg every 3 weeks) or chemotherapy (FOLFIRI or modified FOLFOX-6 with or without bevacizumab or cetuximab).[105]

The median PFS was 16.5 months for patients who received pembrolizumab and 8.2 months for patients who received chemotherapy (HR, 0.60; 95% CI, 0.45–0.80; P = .0002).[105][Level of evidence A3]

Sources: 105 · Level of evidence A3

The PFS in prespecified subgroups showed HRs that favored the pembrolizumab arm, except in patients with KRAS/NRAS variants.

The objective response rate was 43.8% in the pembrolizumab arm and 33.3% in the chemotherapy arm. The median duration of response was not reached in the pembrolizumab arm (range, 2.3–41.4 months) and was 10.6 months in the chemotherapy arm (range, 2.8–37.5 months).

Grade 3 or higher adverse events occurred in 56% of patients who received pembrolizumab (with 9% experiencing grade 3 or higher infusion-related adverse events), compared with 78% of patients who received chemotherapy.

A final review of OS, presented in abstract form, showed that median OS was not reached in the pembrolizumab arm and was 36.7 months in the chemotherapy arm (HR, 0.74; 95% CI, 0.53–1.03; P = .0359).[106]

Sources: 106

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Immunotherapy / First-line immunotherapy

Nivolumab and ipilimumab

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Evidence (nivolumab and ipilimumab):

In a single-arm cohort of the phase II, multicenter CheckMate-142 study (NCT02060188) presented in abstract form, 45 treatment-naïve patients with MSI-H/dMMR metastatic colorectal cancer received nivolumab (3 mg/kg every 2 weeks) with ipilimumab (1 mg/kg every 6 weeks). The primary end point was objective response rate.[107]

Sources: CheckMate-142 · 107

In a single-arm cohort of the phase II, multicenter CheckMate-142 study (NCT02060188) presented in abstract form, 45 treatment-naïve patients with MSI-H/dMMR metastatic colorectal cancer received nivolumab (3 mg/kg every 2 weeks) with ipilimumab (1 mg/kg every 6 weeks). The primary end point was objective response rate.[107]

The objective response rate was 69% among all enrolled patients and 80% for patients with KRAS variants (n = 10).[107][Level of evidence C2]

Sources: 107 · Level of evidence C2

At a 2-year clinical follow-up, the median PFS and OS had not been reached.

In the CheckMate 8HW trial (NCT04008030), published in abstract form, 303 patients who had received various lines of treatment were randomly assigned to receive either nivolumab and ipilimumab (n = 202) or chemotherapy alone (n = 101). Some patients were also randomly assigned to receive nivolumab, but results from these patients were not presented in the abstract. Treatments were continued until disease progression or unacceptable toxicity (all arms), or for up to 2 years (nivolumab-ipilimumab arm). A total of 171 patients who received nivolumab and ipilimumab and 84 patients who received chemotherapy alone were centrally confirmed to have dMMR/MSI-H metastatic colorectal cancer.[108]

Sources: CheckMate 8HW · 108

In the CheckMate 8HW trial (NCT04008030), published in abstract form, 303 patients who had received various lines of treatment were randomly assigned to receive either nivolumab and ipilimumab (n = 202) or chemotherapy alone (n = 101). Some patients were also randomly assigned to receive nivolumab, but results from these patients were not presented in the abstract. Treatments were continued until disease progression or unacceptable toxicity (all arms), or for up to 2 years (nivolumab-ipilimumab arm). A total of 171 patients who received nivolumab and ipilimumab and 84 patients who received chemotherapy alone were centrally confirmed to have dMMR/MSI-H metastatic colorectal cancer.[108]

At a median follow-up of 31.5 months, the PFS was superior for patients who received nivolumab and ipilimumab compared with those who received chemotherapy alone (HR, 0.21; 97.91% CI, 0.13–0.35; P < .0001). Of note, in the chemotherapy arm, 67% of patients received subsequent immunotherapy.

Two grade 5 deaths occurred in the nivolumab-ipilimumab arm. Grade 3 to 4 events occurred in 23% of patients in the nivolumab-ipilimumab arm and 48% of patients in the chemotherapy-alone arm.

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Immunotherapy

Second-line immunotherapy

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Immunotherapy / Second-line immunotherapy

Pembrolizumab monotherapy

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Evidence (pembrolizumab monotherapy):

The FDA approval of pembrolizumab monotherapy was based on data from 149 patients with MSI-H or dMMR cancers enrolled across five uncontrolled, multicohort, multicenter, single-arm clinical trials. Ninety patients had colorectal cancer, and 59 patients were diagnosed with 1 of 14 other cancer types. Patients received either 200 mg of pembrolizumab every 3 weeks or 10 mg/kg of pembrolizumab every 2 weeks. Treatment continued until unacceptable toxicity or disease progression occurred. The major efficacy outcome measures were objective response rate (assessed by blinded independent central radiologists’ review in accordance with Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) and response duration.

The FDA approval of pembrolizumab monotherapy was based on data from 149 patients with MSI-H or dMMR cancers enrolled across five uncontrolled, multicohort, multicenter, single-arm clinical trials. Ninety patients had colorectal cancer, and 59 patients were diagnosed with 1 of 14 other cancer types. Patients received either 200 mg of pembrolizumab every 3 weeks or 10 mg/kg of pembrolizumab every 2 weeks. Treatment continued until unacceptable toxicity or disease progression occurred. The major efficacy outcome measures were objective response rate (assessed by blinded independent central radiologists’ review in accordance with Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) and response duration.

The objective response rate was 39.6% (95% CI, 31.7%–47.9%).

Responses lasted 6 months or longer for 78% of patients who responded to pembrolizumab. There were 11 complete responses and 48 partial responses.

The objective response rate was similar whether patients were diagnosed with colorectal cancer (36%) or a different cancer (46% across the 14 other cancer types).

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Immunotherapy / Second-line immunotherapy

Nivolumab monotherapy

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Evidence (nivolumab monotherapy):

In the CheckMate-142 trial (NCT02060188), 74 patients with previously treated dMMR/MSI-H colorectal cancer were enrolled in an open-label, single-arm, phase II study to receive nivolumab (3 mg/kg every 2 weeks). The primary end point was objective response as per RECIST 1.1.[109]

Sources: CheckMate-142 · 109

In the CheckMate-142 trial (NCT02060188), 74 patients with previously treated dMMR/MSI-H colorectal cancer were enrolled in an open-label, single-arm, phase II study to receive nivolumab (3 mg/kg every 2 weeks). The primary end point was objective response as per RECIST 1.1.[109]

The objective response rate was 31.1% (95% CI, 20.8%–42.9%).

Grade 3 to 4 treatment-related adverse events occurred in 21% of patients.

Health professional · Treatment of Stage IV and Recurrent Colon Cancer / Treatment Options for Stage IV and Recurrent Colon Cancer / Immunotherapy / Second-line immunotherapy

Nivolumab and ipilimumab

Source: Colon Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: February 12, 2025. Captured 2026-09-09.

Evidence (nivolumab and ipilimumab):

CheckMate-142 (NCT02060188) was a multicenter, open-label, phase II trial with a cohort for patients with recurrent or metastatic dMMR and/or MSI-H colorectal cancer who had progressed on, were intolerant of, or declined at least one line of chemotherapy (including 5-FU and oxaliplatin and/or irinotecan). The trial enrolled 119 patients who received four doses of nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) every 3 weeks (induction), then nivolumab (3 mg/kg IV) every 2 weeks (maintenance). The primary end point was objective response rate.[109]

Sources: CheckMate-142 · 109

CheckMate-142 (NCT02060188) was a multicenter, open-label, phase II trial with a cohort for patients with recurrent or metastatic dMMR and/or MSI-H colorectal cancer who had progressed on, were intolerant of, or declined at least one line of chemotherapy (including 5-FU and oxaliplatin and/or irinotecan). The trial enrolled 119 patients who received four doses of nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) every 3 weeks (induction), then nivolumab (3 mg/kg IV) every 2 weeks (maintenance). The primary end point was objective response rate.[109]

The objective response rate was 55% (95% CI, 45.2%–63.8%).

Among patients experiencing a response, 83% had responses lasting more than 6 months.

Grade 3 to 4 treatment-related adverse events occurred in 32% of patients.

For patients · General Information About Colon Cancer

Certain factors affect prognosis (chance of recovery) and treatment options.

Source: Colon Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

The prognosis and treatment options depend on:

the stage of the cancer (whether it affects the inner lining of the colon only, or has spread to lymph nodes, nearby organs, or other places in the body)

Sources: stage · lymph nodes

the level of CEA in the blood

Sources: CEA

whether the cancer is related to certain genetic changes in stool cells

whether the tumor has spread into or through the colon wall

whether the colon is blocked or has a hole in it

whether all of the tumor can be removed by surgery

the patient's general health

whether the cancer has just been diagnosed or has recurred (come back)

For patients · Stages of Colon Cancer

Colon cancer can recur (come back) after it has been treated.

Source: Colon Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Recurrent colon cancer is cancer that has come back after it has been treated. If colon cancer comes back, it may come back in the colon or in other parts of the body, such as the liver, lungs, or both. Tests will be done to help determine where the cancer has returned. The type of treatment for recurrent colon cancer will depend on where it has come back.

Learn more in Recurrent Cancer: When Cancer Comes Back.

Sources: Recurrent Cancer: When Cancer Comes Back

For patients

Treatment Option Overview

Source: Colon Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview

Key Points

Source: Colon Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

There are different types of treatment for people with colon cancer.

The following types of treatment are used:

The following types of treatment are used:

Surgery

Chemotherapy

Radiation therapy

Targeted therapy

Immunotherapy

New types of treatment are being tested in clinical trials.

Treatment for colon cancer may cause side effects.

Follow-up care may be needed.

For patients · Treatment Option Overview

There are different types of treatment for people with colon cancer.

Source: Colon Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Different types of treatments are available for colon cancer. You and your cancer care team will work together to decide your treatment plan, which may include more than one type of treatment. Many factors will be considered, such as the stage of the cancer, your overall health, and your preferences. Your plan will include information about your cancer, the goals of treatment, your treatment options and the possible side effects, and the expected length of treatment.

Talking with your cancer care team before treatment begins about what to expect will be helpful. You’ll want to learn what you need to do before treatment begins, how you’ll feel while going through it, and what kind of help you will need. To learn more, visit Questions to Ask Your Doctor About Treatment.

Sources: Questions to Ask Your Doctor About Treatment

For patients · Treatment Option Overview

The following types of treatment are used:

Source: Colon Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

For patients · Treatment Option Overview / The following types of treatment are used:

Surgery

Source: Colon Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Surgery is the most common treatment for all stages of colon cancer. The cancer is removed using one of the following types of surgery:

Sources: stages

Polypectomy: If the cancer is found in a polyp (a small piece of bulging tissue), the polyp is often removed during a colonoscopy.

Sources: colonoscopy

Local excision: If the cancer is found at a very early stage, the doctor may remove it without cutting through the abdominal wall. Instead, the doctor may put a tube with a cutting tool through the rectum into the colon and cut the cancer out. This is called a local excision.

Sources: abdominal

Resection of the colon with anastomosis: If the cancer is larger, the doctor will perform a partial colectomy (removing the cancer and a small amount of healthy tissue around it). The doctor may then perform an anastomosis (sewing the healthy parts of the colon together). The doctor will also usually remove lymph nodes near the colon and examine them under a microscope to see whether they contain cancer.

Sources: anastomosis · colectomy · lymph nodes

Resection of the colon with colostomy: If the doctor is not able to sew the two ends of the colon back together, a stoma (opening) is made on the outside of the body for waste to pass through. This procedure is called a colostomy. A bag is placed around the stoma to collect the waste. Sometimes the colostomy is needed only until the lower colon has healed, and then it can be reversed. If the doctor needs to remove the entire lower colon, however, the colostomy may be permanent.

Sources: colostomy · stoma

Radiofrequency ablation: The use of a special probe with tiny electrodes that kill cancer cells. Sometimes, the probe is inserted directly through the skin, and only local anesthesia is needed. In other cases, the probe is inserted through an incision in the abdomen. This is done in the hospital with general anesthesia.

Sources: electrodes · local anesthesia · incision · abdomen · general anesthesia

Cryosurgery: A treatment that uses an instrument to freeze and destroy abnormal tissue. This type of treatment is also called cryotherapy. Learn more about Cryosurgery to Treat Cancer.

Sources: Cryosurgery · abnormal · Cryosurgery to Treat Cancer

Radiation therapy and/or chemotherapy may be given before surgery to shrink the tumor, make it easier to remove the cancer, and help with bowel control after surgery. Treatment given before surgery is called neoadjuvant therapy. After all the cancer that can be seen at the time of the surgery is removed, some patients may be given radiation therapy and/or chemotherapy after surgery to kill any cancer cells that are left. Treatment given after the surgery, to lower the risk that the cancer will come back, is called adjuvant therapy.

Sources: Radiation therapy · chemotherapy · bowel · neoadjuvant therapy · adjuvant therapy

If the cancer has spread to the liver and cannot be removed by surgery, a total hepatectomy and liver transplant after chemotherapy may be done. Total hepatectomy and liver transplant is the removal of the entire liver by surgery, followed by a transplant of a healthy liver from a donor.

For patients · Treatment Option Overview / The following types of treatment are used:

Chemotherapy

Source: Colon Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.

Systemic chemotherapy is when chemotherapy drugs are taken by mouth or injected into a vein or muscle. When given this way, the drugs enter the bloodstream and can reach cancer cells throughout the body. Systemic chemotherapy used to treat colon cancer includes:

Sources: injected

capecitabine

Sources: capecitabine

fluorouracil (5-FU)

Sources: fluorouracil (5-FU)

irinotecan

Sources: irinotecan

leucovorin (a vitamin that improves the effectiveness of 5-FU)

Sources: leucovorin

oxaliplatin

Sources: oxaliplatin

trifluridine and tipiracil

Sources: trifluridine and tipiracil

Combinations of these drugs may be used. Other chemotherapy drugs not listed here may also be used.

Chemotherapy may also be combined with other kinds of drugs. For example, it might be combined with the targeted therapy drug bevacizumab, cetuximab, or panitumumab.

Sources: bevacizumab · cetuximab · panitumumab

Regional chemotherapy for colon cancer is when drugs are placed directly into the hepatic artery (the main artery that supplies blood to the liver) in a procedure called chemoembolization. Chemoembolization of the hepatic artery may be used to treat cancer that has spread to the liver. This is done by blocking the hepatic artery and injecting anticancer drugs between the blockage and the liver. The liver’s arteries then carry the drugs into the liver. Only a small amount of the drug reaches other parts of the body. The blockage may be temporary or permanent, depending on what is used to block the artery. The liver continues to receive some blood from the hepatic portal vein, which carries blood from the stomach and intestine.

Sources: artery · liver · hepatic portal vein · stomach · intestine

The way the chemotherapy is given depends on the type and stage of the cancer being treated.

Learn more about how chemotherapy works, how it is given, common side effects, and more at Chemotherapy to Treat Cancer and Chemotherapy and You: Support for People With Cancer.

Sources: Chemotherapy to Treat Cancer · Chemotherapy and You: Support for People With Cancer

For patients · Treatment Option Overview / The following types of treatment are used:

Radiation therapy

Source: Colon Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Colon cancer is sometimes treated with two types of radiation therapy used to treat colon cancer:

Sources: radiation

External radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer.

Sources: External radiation therapy

Internal radiation therapy uses a radioactive substance sealed in needles, seeds, wires, or catheters that are placed directly into or near the cancer. Internal radiation therapy may be used to treat colon cancer that has spread to the liver.

Sources: Internal radiation therapy · radioactive · seeds · catheters

Learn more about Radiation Therapy to Treat Cancer and Radiation Therapy Side Effects.

Sources: Radiation Therapy to Treat Cancer · Radiation Therapy Side Effects

For patients · Treatment Option Overview / The following types of treatment are used:

Targeted therapy

Source: Colon Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Targeted therapy uses drugs or other substances to identify and attack specific cancer cells. Your doctor may suggest biomarker tests to help predict your response to certain targeted therapy drugs. Learn more about Biomarker Testing for Cancer Treatment.

Sources: biomarker tests · Biomarker Testing for Cancer Treatment

Targeted therapies used to treat colon cancer include:

bevacizumab

Sources: bevacizumab

cetuximab

Sources: cetuximab

encorafenib

Sources: encorafenib

fruquintinib

Sources: fruquintinib

panitumumab

Sources: panitumumab

ramucirumab

Sources: ramucirumab

regorafenib

Sources: regorafenib

ziv-aflibercept

Sources: ziv-aflibercept

Learn more about Targeted Therapy to Treat Cancer.

Sources: Targeted Therapy to Treat Cancer

For patients · Treatment Option Overview / The following types of treatment are used:

Immunotherapy

Source: Colon Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Immunotherapy helps a person’s immune system fight cancer. Your doctor may suggest biomarker tests to help predict your response to certain immunotherapy drugs. Learn more about Biomarker Testing for Cancer Treatment.

Sources: Biomarker Testing for Cancer Treatment

Immunotherapy drugs used to treat colon cancer include:

ipilimumab

Sources: ipilimumab

nivolumab

Sources: nivolumab

pembrolizumab

Sources: pembrolizumab

Learn more about Immunotherapy to Treat Cancer.

Sources: Immunotherapy to Treat Cancer

For patients · Treatment Option Overview

New types of treatment are being tested in clinical trials.

Source: Colon Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

For some people, joining a clinical trial may be an option. There are different types of clinical trials for people with cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.

You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trial search · ClinicalTrials.gov

Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.

Sources: Clinical Trials Information for Patients and Caregivers

For patients · Treatment Option Overview

Treatment for colon cancer may cause side effects.

Source: Colon Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

For information about side effects caused by treatment for cancer, visit our Side Effects page.

Sources: side effects · Side Effects

For patients · Treatment Option Overview

Follow-up care may be needed.

Source: Colon Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

As you go through treatment, you will have follow-up tests or check-ups. Some tests that were done to diagnose or stage the cancer may be repeated to see how well the treatment is working. Decisions about whether to continue, change, or stop treatment may be based on the results of these tests.

Sources: diagnose · stage

Some of the tests will continue to be done from time to time after treatment has ended. The results of these tests can show if your condition has changed or if the cancer has recurred (come back).

After treatment for colon cancer, a blood test to measure amounts of carcinoembryonic antigen (a substance in the blood that may be increased when cancer is present) may be done to see if the cancer has come back.

Sources: blood test · carcinoembryonic antigen

For patients

Treatment of Stage 0 (carcinoma in situ)

Source: Colon Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Treatment of stage 0 may include the following types of surgery:

Sources: stage 0

simple polypectomy

Sources: polypectomy

local excision

Sources: local · excision

resection and anastomosis (when the tumor is too large to remove by local excision)

Sources: resection · anastomosis

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stages I and II Colon Cancer

Source: Colon Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Treatment of stage I colon cancer and stage II colon cancer may include resection and anastomosis.

Sources: stage I colon cancer · stage II colon cancer · resection · anastomosis

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stage III Colon Cancer

Source: Colon Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Treatment of stage III colon cancer may include resection and anastomosis, which may be followed by chemotherapy.

Sources: stage III colon cancer · resection · anastomosis · chemotherapy

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Treatment of Stage IV and Recurrent Colon Cancer

Source: Colon Cancer Treatment (PDQ®)–Patient Version, National Cancer Institute.

Source updated: May 16, 2025. Captured 2026-09-09.

Treatment of stage IV colon cancer, recurrent colon cancer, and liver metastasis may include:

Sources: stage IV colon cancer · recurrent · liver metastasis

local excision for tumors that have recurred

Sources: local · excision · recurred

resection with or without anastomosis

Sources: resection · anastomosis

surgery to remove parts of other organs, such as the liver, lungs, and ovaries, where the cancer may have recurred or spread

Sources: liver · lungs · ovaries

radiation therapy or chemotherapy, as palliative therapy to relieve symptoms and improve quality of life

Sources: radiation therapy · chemotherapy · palliative therapy · symptoms · quality of life

chemotherapy with or without targeted therapy (bevacizumab, cetuximab, fruquintinib, panitumumab, ramucirumab, or regorafenib, or ziv-aflibercept)

Sources: targeted therapy · bevacizumab · cetuximab · fruquintinib · panitumumab · ramucirumab · regorafenib · ziv-aflibercept

targeted therapy with encorafenib and cetuximab in patients with a certain change in the BRAF gene

Sources: encorafenib · BRAF

immunotherapy (nivolumab or pembrolizumab, or nivolumab and ipilimumab combined)

Sources: immunotherapy · nivolumab · pembrolizumab · ipilimumab

Treatment of cancer that has spread to the liver may also include:

chemotherapy given before surgery to shrink the tumor, after surgery, or both before and after

radiofrequency ablation or cryosurgery, for patients who cannot have surgery

Sources: radiofrequency ablation · cryosurgery

chemoembolization of the hepatic artery

Sources: chemoembolization · hepatic artery

liver transplant after chemotherapy for patients with liver metastases that cannot be removed by surgery

Learn more about these treatments in the Treatment Option Overview.

Sources: Treatment Option Overview

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

Studies

Combination Chemotherapy in Treating Patients With Stage III Colon Cancer

NCT00003835 · COMPLETED · phase3

Adenocarcinoma of the Colon, Stage III Colon Cancer

ClinicalTrials.gov record

Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer

NCT00004931 · COMPLETED · phase3

Stage II Colon Cancer, Stage III Colon Cancer

ClinicalTrials.gov record

Leucovorin and Fluorouracil Compared With Observation in Treating Patients With Colorectal Cancer That Has Been Surgically Removed

NCT00005586 · COMPLETED · phase3

Colorectal Cancer

ClinicalTrials.gov record

Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer

NCT00006479 · UNKNOWN · phase3

Colorectal Cancer, Metastatic Cancer

ClinicalTrials.gov record

A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer

NCT00009737 · COMPLETED · phase3

Colorectal Cancer

ClinicalTrials.gov record

Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated

NCT00025337 · COMPLETED · phase3

Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon...

ClinicalTrials.gov record

Combination Chemotherapy in Treating Patients With Colon Cancer

NCT00046995 · UNKNOWN · phase3

Colorectal Cancer

ClinicalTrials.gov record

Bevacizumab Plus Fluorouracil and Leucovorin in Treating Patients With Locally Advanced or Metastatic Stage IV Colorectal Cancer That Has Progressed After Standard Chemotherapy

NCT00066846 · COMPLETED · phase2

Colorectal Cancer

ClinicalTrials.gov record

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

NCT00069095 · COMPLETED · phase3

Colorectal Cancer

ClinicalTrials.gov record

A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer

NCT00069121 · COMPLETED · phase3

Colorectal Cancer

ClinicalTrials.gov record

Cetuximab + Best Supportive Care Compared With Best Supportive Care Alone in Metastatic Epidermal Growth Factor Receptor-Positive Colorectal Cancer

NCT00079066 · COMPLETED · phase3

Colorectal Cancer, Quality of Life

ClinicalTrials.gov record

Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer

NCT00096278 · COMPLETED · phase3

Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v7, Stage IIB Colon Cancer AJCC v7, Stage IIC Colon Cancer AJCC v7, Stage IIIA Colon Cancer AJCC v7, Stage IIIB Colon Cancer...

ClinicalTrials.gov record

A Study to Evaluate Avastin in Combination With Standard Chemotherapy to Treat Colorectal Cancer

NCT00109070 · COMPLETED · phase3

Colorectal Cancer

ClinicalTrials.gov record

Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer

NCT00112918 · COMPLETED · phase3

Colorectal Cancer

ClinicalTrials.gov record

Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer

NCT00113763 · COMPLETED · phase3

Colorectal Cancer, Metastases

ClinicalTrials.gov record

MOSAIC - Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer

NCT00275210 · COMPLETED · phase3

Colonic Neoplasms

ClinicalTrials.gov record

Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery

NCT00304135 · COMPLETED · phase2, phase3

Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer

ClinicalTrials.gov record

Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen

NCT00561470 · COMPLETED · phase3

Colorectal Neoplasms, Neoplasm Metastasis

ClinicalTrials.gov record

A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.

NCT00700102 · COMPLETED · phase3

Colorectal Cancer

ClinicalTrials.gov record

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

NCT01001377 · COMPLETED · phase3

Metastatic Colorectal Cancer

ClinicalTrials.gov record

Comparison of Survival Benefit of Panitumumab With Supportive Care to Best Supportive Care Alone in Patients With Metastatic Colorectal Cancer

NCT01412957 · COMPLETED · phase3

Metastatic Colorectal Cancer

ClinicalTrials.gov record

A Phase III Trial Evaluating Fruquintinib Efficacy and Safety in 3+ Line Colorectal Cancer Patients (FRESCO)

NCT02314819 · COMPLETED · phase3

Colorectal Cancer

ClinicalTrials.gov record

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

NCT02912559 · ACTIVE NOT RECRUITING · phase3

Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer AJCC v8

ClinicalTrials.gov record

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer

NCT03043313 · COMPLETED · phase2

Metastatic Colorectal Adenocarcinoma

ClinicalTrials.gov record

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

NCT04607421 · ACTIVE NOT RECRUITING · phase3

Neoplasms

ClinicalTrials.gov record

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

NCT01730586 · COMPLETED · phase2

Colorectal Cancer, Cancer of Gastrointestinal Tract

ClinicalTrials.gov record

HIPEC for Peritoneal Carcinomatosis

NCT02040142 · COMPLETED · phase2

Peritoneal Carcinomatosis, Colorectal Cancer, Appendiceal Cancer, Peritoneal Mesothelioma, Pseudomyxoma Peritonei, Gastric Cancer

ClinicalTrials.gov record

Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy

NCT04526886 · COMPLETED · na

Colorectal Cancer, Gastric Cancer, Esophageal Cancer, Ampullary Cancer, Small Bowel Cancer, Appendix Cancer

ClinicalTrials.gov record

Disease and treatment settings

Appendix Neoplasm

Disease and treatment setting

Appendix Neoplasm

Camptosar: metastatic Carcinoma of the Colon (first-line)

Disease and treatment setting

• First-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic carcinoma of the colon or rectum.

Camptosar: metastatic Carcinoma of the Colon after prior therapy

Disease and treatment setting

• Patients with metastatic carcinoma of the colon or rectum whose disease has recurred or progressed following initial fluorouracil-based therapy.

Colon Cancer

Disease and treatment setting

Neoadjuvant chemotherapy for unresectable liver metastases

Colon Cancer

Disease and treatment setting

Adjuvant or neoadjuvant chemotherapy for resectable liver metastases

Colon Cancer

Disease and treatment setting

Colon Cancer

Colorectal Neoplasm

Disease and treatment setting

Colorectal Neoplasm

Malignant Appendix Neoplasm

Disease and treatment setting

Malignant Appendix Neoplasm

Stage 0 Colon Cancer

Disease and treatment setting

Treatment of Stage 0 Colon Cancer

Stage I Colon Cancer

Disease and treatment setting

Treatment of Stage I Colon Cancer

Stage II Colon Cancer

Disease and treatment setting

Treatment of Stage II Colon Cancer

Stage III Colon Cancer

Disease and treatment setting

Treatment of Stage III Colon Cancer

Stage IV recurrent Colon Cancer

Disease and treatment setting

Treatment of Stage IV and Recurrent Colon Cancer

XELODA: Colon Cancer (adjuvant)

Disease and treatment setting

1 INDICATIONS AND USAGE XELODA (capecitabine) is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination...

Drug labels

ALYMSYS

Label date 2026-01-27

Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. (1.1)...

DailyMed label

ALYMSYS

Label date 2026-03-23

Alymsys is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. (1.1)...

DailyMed label

Avastin

Label date 2025-01-06

Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 )...

DailyMed label

BRAFTOVI

Label date 2026-02-26

BRAFTOVI is a kinase inhibitor indicated: Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-authorized test. (...

DailyMed label

ERBITUX

Label date 2026-04-16

ERBITUX ® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of: Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. ( 1.1...

DailyMed label

Fruzaqla

Label date 2026-07-31

1. INDICATIONS AND USAGE FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an...

DailyMed label

JOBEVNE

Label date 2026-03-11

Jobevne is a vascular endothelial growth factor inhibitor indicated for the treatment of: • Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first-or second-line treatment. ( 1.1 ) •...

DailyMed label

KHAPZORY

Label date 2026-03-17

KHAPZORY is indicated for: rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination...

DailyMed label

LONSURF

Label date 2025-11-05

LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with: metastatic colorectal cancer as a single agent or in...

DailyMed label

MVASI

Label date 2026-06-23

MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 )...

DailyMed label

Vectibix

Label date 2026-06-23

Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of: Adult patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test) Metastatic Colorectal...

DailyMed label

Vegzelma

Label date 2026-08-21

VEGZELMA is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 )...

DailyMed label

VYKOURA

Label date 2026-03-12

VYKOURA is indicated for: 1.1 Rescue after high-dose methotrexate (MTX) therapy in adult and pediatric patients. 1.2 Reducing the toxicity of: Methotrexate in adult and pediatric patients with impaired methotrexate elimination or Folic...

DailyMed label

XELODA

Label date 2026-02-05

XELODA (capecitabine) is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 )...

DailyMed label

ZALTRAP

Label date 2025-10-06

ZALTRAP, in combination with fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing...

DailyMed label

Zirabev

Label date 2026-07-21

ZIRABEV is a vascular endothelial growth factor inhibitor indicated for the treatment of: • Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) •...

DailyMed label